Introduction
============

Appropriate pharmacological management of COPD involves treatment with inhaled bronchodilators to reduce airflow limitation and hyperinflation. Most patient groups identified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy can be managed using long-acting inhaled bronchodilators (long-acting muscarinic antagonists \[LAMAs\] and long-acting β~2~-agonists \[LABAs\]), with or without inhaled corticosteroids.[@b1-copd-12-141] Fixed dose combinations (FDCs) provide potent bronchodilation versus single agents,[@b2-copd-12-141] with some advantage in terms of convenience and simplicity compared with combinations administered via separate inhalers. Beta agonists (BAs) and muscarinic antagonists (MAs) target different pathways to promote smooth-muscle relaxation and inhibit pulmonary constriction. Combining bronchodilators with different modes of action appears to be additive, providing greater efficacy versus component monotherapies.[@b3-copd-12-141] Randomized controlled trials (RCTs) of LABA--LAMA combinations via separate inhalers have generally shown improved lung function versus component monotherapies.[@b4-copd-12-141]--[@b12-copd-12-141]

COPD is characterized by persistent airflow limitation, with forced expiratory volume in 1 second (FEV~1~) to forced vital capacity ratio and percentage predicted FEV~1~ widely used as pathophysiological markers.[@b1-copd-12-141] However, COPD is multidimensional, with pulmonary, extrapulmonary, and systemic effects. Outcomes in addition to FEV~1~ are needed to assess disease burden and treatment efficacy.[@b13-copd-12-141] Spirometry is central to COPD diagnosis, but does not measure COPD burden in terms of health status.[@b14-copd-12-141] Additionally, spirometry is not always performed, and symptoms and exacerbation history can play important roles in treatment initiation and management.[@b15-copd-12-141] It is therefore important that spirometry is accompanied by assessments using patient-reported outcome (PRO) measures, such as breathlessness, physical functioning, and health status.[@b14-copd-12-141] Minimal clinically important differences (MCIDs) for these assessments and other COPD outcomes have been reviewed by Jones et al.[@b14-copd-12-141] Although a few studies and reports have examined associations between improved lung function (mainly FEV~1~) and PROs in COPD,[@b16-copd-12-141]--[@b21-copd-12-141] the relationship between these efficacy measures is often weak, particularly for LAMAs and LABA--LAMA combinations. Here, we examine the evidence for the use of FDC bronchodilators in COPD, assess effects on PROs, and evaluate relationships between PROs and changes in lung function.

Materials and methods
=====================

This systematic literature search (not registered) was performed in accordance with the general principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[@b22-copd-12-141] The literature search identified primary, English-language, RCT publications of fixed-combination bronchodilators reporting treatment effects on lung function and/or PROs in comparison with placebo, bronchodilator monotherapy, or inhaled corticosteroid--LABA combinations in patients with COPD ([Table S1](#SD1-copd-12-141){ref-type="supplementary-material"}). Data sources included a ProQuest search of Biosis, Biosis previews, Embase and Medline databases (January 1, 2006 to July 31, 2014), and abstracts from principal respiratory congresses (January 1, 2009 to May 20, 2015; [Table S2](#SD2-copd-12-141){ref-type="supplementary-material"}). These selected search dates ensured that all relevant publications on fixed-combination bronchodilators were captured. Following the publication-database searches and during preparation of this manuscript (August 2015 onward), additional relevant articles became available, and thus these were added to the literature-search results.

All search results were extracted and gathered by a single party. Titles and abstracts were then scrutinized in parallel by two independent reviewers, and papers were categorized as relevant (where both reviewers categorized a paper as "relevant"), not relevant (where both reviewers judged a paper as "not relevant"), or potentially relevant (where one reviewer judged a paper as "relevant" and the other judged the same paper as "not relevant"). Irrelevant publications/studies comprised review papers, unapproved treatment doses, nonclinical trials, incorrect drug, or incorrect disease. Conflicting results were resolved by a third reviewer, who provided input as to whether the abstract was of potential relevance based on the same criteria as the first reviewers. To reduce the risk of omitting relevant studies/papers, all relevant and potentially relevant results were subsequently reviewed by the authors, who had the final decision regarding which publications to take to the next review level. Where relevance was not discernible from abstracts, full copies of author-confirmed relevant/potentially relevant articles were further assessed by two reviewers and conflicts resolved by a third reviewer. Data from the literature describing treatment differences with the FDC and comparator are summarized -- according to end point -- using least-squares mean (LSM) and 95% confidence interval (95% CI), odds ratio (OR), rate ratio, or hazard ratio (HR).

Results
=======

Systematic literature-search results
------------------------------------

The searches yielded 729 records, from which 35 primary publications were relevant ([Figure 1](#f1-copd-12-141){ref-type="fig"}). Literature searches were supplemented with information from [ClinicalTrials.gov](http://ClinicalTrials.gov), and author expertise/knowledge (eg, if authors were aware that important publications were missing from search results).[@b23-copd-12-141] Between the time of the predefined search end (July 2014 for published manuscripts and May 2015 for congress abstracts) and the drafting of this manuscript (August 2015 onwards), additional FDC studies were being published, and are thus included in this review.[@b23-copd-12-141]--[@b34-copd-12-141]

Trials of fixed-dose dual-combination bronchodilators
-----------------------------------------------------

FDC bronchodilators approved or in advanced clinical development for COPD include: indacaterol--glycopyrronium once daily (OD; QVA149; Ultibro^®^ Breezhaler^®^; Novartis International AG, Basel, Switzerland), umeclidinium--vilanterol 110/50 µg OD (Laventair/Anoro^®^ Ellipta^®^; GlaxoSmithKline PLC, London, UK), tiotropium--olodaterol OD (Spiolto^®^ Respimat^®^; Boehringer Ingelheim, Ingelheim, Germany), aclidinium--formoterol twice daily (bis in die \[BID\]; Duaklir^®^ Genuair^®^; AstraZeneca PLC, London, UK) and glycopyrrolate--formoterol (PT003; AstraZeneca).

Indacaterol--glycopyrronium OD is approved in \>70 countries. Of 13 large Phase III trials of indacaterol--glycopyrronium, publications are available for ten (SHINE, ILLUMINATE, BRIGHT, ENLIGHTEN, SPARK, BLAZE, BEACON, LANTERN, QUANTIFY, and FLAME), all of which report lung function and PRO data and are included in this review ([Table 1](#t1-copd-12-141){ref-type="table"}).[@b2-copd-12-141],[@b24-copd-12-141]--[@b26-copd-12-141],[@b35-copd-12-141]--[@b40-copd-12-141] These active-comparator and placebo-controlled trials ranged from 3 to 64 weeks in duration.

Umeclidinium--vilanterol 62.5/25 µg OD is approved in the US and EU (higher doses are not reviewed here). Findings from 12 Phase III trials had been reported in publications or conference abstracts at the time of the literature search, including: five 24-week studies,[@b23-copd-12-141],[@b32-copd-12-141],[@b41-copd-12-141] seven 12-week studies,[@b27-copd-12-141],[@b33-copd-12-141],[@b42-copd-12-141],[@b43-copd-12-141] and one 52-week safety study (125/25 µg).[@b45-copd-12-141] Lung-function and PRO data have been fully reported for six of the eight trials listed in [Table 1](#t1-copd-12-141){ref-type="table"}.[@b23-copd-12-141],[@b27-copd-12-141],[@b32-copd-12-141],[@b41-copd-12-141]

Tiotropium--olodaterol (5/5 µg; lower doses are not reviewed) OD has been approved in more than 20 European countries, the US, Canada, and Australia since May 2015. Results from two 1-year studies with tiotropium--olodaterol 5/5 µg (included in this review; [Table 1](#t1-copd-12-141){ref-type="table"}) have been reported and include data on lung function and health status versus the monocomponents.[@b30-copd-12-141] Results from an additional Phase III trial evaluating lung function and volume (VIVACITO) have been published ([Table 1](#t1-copd-12-141){ref-type="table"}),[@b31-copd-12-141] two Phase III trials have been presented as abstracts,[@b34-copd-12-141],[@b45-copd-12-141] one further Phase III study has been completed ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT01536262) and four are ongoing ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT02006732, NCT01964352, NCT01969721, and NCT02085161).

Aclidinium--formoterol (400/12 µg BID) is approved in the EU. Findings from two of four Phase III trials have been fully reported comparing the combination therapy versus monocomponents or placebo, and are included in this paper ([Table 1](#t1-copd-12-141){ref-type="table"}).[@b28-copd-12-141],[@b29-copd-12-141],[@b46-copd-12-141] Results from a 24-week Phase III study comparing aclidinium--formoterol with salmeterol--fluticasone combination (SFC) BID had been published in abstract form at the time of the literature search.[@b47-copd-12-141] For glycopyrrolate--formoterol (in late-stage development), only Phase II congress abstracts are available.[@b48-copd-12-141]--[@b50-copd-12-141] Three Phase III studies are ongoing ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT01854645, NCT01854658, and NCT01970878).

In this review, we focus on the 23 aforementioned published Phase III RCTs and listed in [Table 1](#t1-copd-12-141){ref-type="table"} (supplemented with results presented at major respiratory congresses, where applicable): ten with indacaterol--glycopyrronium OD, eight with umeclidinium--vilanterol OD, three with tiotropium--olodaterol OD, and two with aclidinium--formoterol BID. The remaining primary publications from the literature search were excluded, due to duplicate publications of the same results (eg, where a primary publication superseded several congress abstracts).

Patient population and study design
-----------------------------------

Patient populations, inclusion criteria, treatment blinding, and other characteristics differed between trials ([Table 1](#t1-copd-12-141){ref-type="table"}). The majority of indacaterol--glycopyrronium OD studies enrolled symptomatic patients with moderate-to-severe airflow limitation (GOLD 2008, 2009, or 2010 classification), except for SPARK and FLAME, which enrolled patients with severe-to-very-severe or moderate-to-very-severe disease, respectively, and one or more exacerbations in the past year.[@b2-copd-12-141],[@b24-copd-12-141],[@b26-copd-12-141],[@b35-copd-12-141]--[@b40-copd-12-141] The eight umeclidinium--vilanterol OD trials enrolled patients with moderate-to-severe or moderate-to-very-severe COPD who were symptomatic.[@b23-copd-12-141],[@b27-copd-12-141],[@b32-copd-12-141],[@b41-copd-12-141] Patients in the tiotropium--olodaterol OD studies had moderate-to-very-severe COPD.[@b30-copd-12-141],[@b31-copd-12-141] The aclidinium--formoterol BID studies were conducted in patients with moderate-to- severe COPD.[@b28-copd-12-141],[@b29-copd-12-141]

Lung function
-------------

Across eight trials (3--64 weeks), indacaterol--glycopyrronium OD provided significant LSM treatment differences in trough FEV~1~ of 60--80 mL versus tiotropium 18 µg, 70--80 mL versus indacaterol 150 µg or glycopyrronium 50 µg alone, 68 mL versus tiotropium + formoterol 18/12 µg, 62--72 mL versus SFC 50/500 µg BID, and 189--200 mL versus placebo ([Table 2](#t2-copd-12-141){ref-type="table"}).[@b2-copd-12-141],[@b24-copd-12-141]--[@b26-copd-12-141],[@b35-copd-12-141],[@b36-copd-12-141],[@b39-copd-12-141],[@b40-copd-12-141] Preliminary data suggest that the extent of FEV~1~ improvement may vary: in a post hoc analysis of SHINE, data from patients in the spirometry subset who received indacaterol--glycopyrronium OD (n=399) showed that 39.8% had an increase in FEV~1~ of ≥200 mL between baseline and week 26, 23.8% achieved ≥300 mL, and 13.1% had an increase of ≥400 mL.[@b51-copd-12-141]

In three Phase III studies, LSM treatment differences in trough-FEV~1~ change from baseline to week 24 with umeclidinium--vilanterol 62.5/25 µg OD were 60--112 mL versus tiotropium 18 µg, 52 mL versus umeclidinium 62.5 µg, 22 mL versus umeclidinium 125 µg (not statistically significant), 90--95 mL versus vilanterol 25 µg, and 167 mL versus placebo.[@b23-copd-12-141],[@b32-copd-12-141],[@b41-copd-12-141] In two 12-week studies, umeclidinium--vilanterol 62.5/25 µg produced greater increases in trough FEV~1~ versus individual components.[@b33-copd-12-141] In another two 12-week studies, umeclidinium--vilanterol 62.5/25 µg resulted in significant improvements in FEV~1~ 0--24 hours and trough FEV1 compared with 50/250 μg BID.[@b27-copd-12-141]

At week 24 of the two 1-year studies, tiotropium--olodaterol 5/5 μg OD increased trough FEV1 by 82--88 mL versus olodaterol 5 μg and by 50--71 mL versus tiotropium 5 μg.[@b30-copd-12-141] A 6-week incomplete crossover study showed improvements in 24-hour lung function with tiotropium--olodaterol 5/5 µg versus components or placebo.[@b31-copd-12-141]

Aclidinium--formoterol (400/12 μg BID) increased week 24 trough FEV~1~ significantly versus placebo (143 mL) and formoterol (85 mL) in the ACLIFORM study, but the smaller difference (\~25 mL) versus aclidinium BID was not statistically significant.[@b28-copd-12-141] Similar results were observed in the AUGMENT trial, with a significant difference for the combination versus formoterol (45 mL), but not aclidinium (28 mL).[@b29-copd-12-141]

Symptoms
--------

Improvements in dyspnea and other symptoms were seen with fixed-dose LABA--LAMA therapies versus monotherapies and for indacaterol--glycopyrronium OD versus SFC BID. ([Table 3](#t3-copd-12-141){ref-type="table"}, [Figure 2](#f2-copd-12-141){ref-type="fig"}).[@b2-copd-12-141],[@b24-copd-12-141],[@b25-copd-12-141],[@b38-copd-12-141],[@b39-copd-12-141] Indacaterol--glycopyrronium significantly improved transition dyspnea index (TDI) scores in SHINE and ILLUMINATE versus placebo, open-label tiotropium, and SFC.[@b2-copd-12-141],[@b39-copd-12-141] In BLAZE, indacaterol--glycopyrronium significantly improved self-administered computerized total TDI score versus placebo (LSM treatment difference 1.37, *P*\<0.001) and blinded tiotropium (LSM treatment difference: 0.49, *P*=0.021).[@b38-copd-12-141] The proportion of patients achieving the MCID (≥1-point) for TDI score was also significantly increased versus blinded tiotropium in BLAZE (OR 1.78, *P*\<0.05) and versus SFC in ILLUMINATE (OR 1.56, *P*\<0.05; [Figure 2](#f2-copd-12-141){ref-type="fig"}).[@b2-copd-12-141],[@b39-copd-12-141] In QUANTIFY, a similar reduction in dyspnea was observed with indacaterol--glycopyrronium versus tiotropium + formoterol, and significantly more patients achieved clinically relevant improvements in TDI total score with indacaterol--glycopyrronium (49.6%) versus tiotropium + formoterol (42.4%, *P*=0.033).[@b25-copd-12-141]

In LANTERN, a comparable improvement with indacaterol--glycopyrronium OD and SFC BID was demonstrated for TDI focal score and St George's Respiratory Questionnaire (SGRQ) total score from baseline after 26 weeks; the percentage of patients achieving the MCID for both end points was higher with indacaterol--glycopyrronium versus SFC.[@b24-copd-12-141] Compared with its component monotherapies, indacaterol--glycopyrronium was associated with numerical improvements in TDI score and percentage of TDI responders at week 26 in SHINE.[@b2-copd-12-141] At week 12, improvement in TDI score with indacaterol--glycopyrronium was significantly greater than with glycopyrronium (LSM treatment difference 0.41, *P*=0.03).

Three indacaterol--glycopyrronium OD studies evaluated patient-diary data and reported significantly improved symptom scores versus indacaterol, glycopyrronium, tiotropium, or placebo ([Table 3](#t3-copd-12-141){ref-type="table"}).[@b2-copd-12-141],[@b36-copd-12-141],[@b38-copd-12-141] In the shorter BRIGHT trial, change in mean daily symptom score from baseline to week 3 was numerically greater for indacaterol--glycopyrronium versus tiotropium and placebo.[@b35-copd-12-141] In ILLUMINATE, differences in scores for most symptoms were comparable for indacaterol--glycopyrronium and SFC BID.[@b39-copd-12-141]

In three 24-week studies, umeclidinium--vilanterol 62.5/25 µg OD significantly improved TDI focal and Shortness of Breath with Daily Activity (SOBDA) scores versus placebo, with numerical improvements versus mono-components and tiotropium.[@b23-copd-12-141],[@b41-copd-12-141] The proportion of patients achieving the MCID for TDI score was significantly increased in patients receiving umeclidinium--vilanterol versus placebo (OR 2, *P*\<0.001) and vilanterol (OR 1.4, *P*\<0.05)[@b41-copd-12-141] in one study ([Figure 2](#f2-copd-12-141){ref-type="fig"}).[@b23-copd-12-141] LSM changes from baseline to week 24 in SOBDA scores were clinically significant (≥0.1 unit) for umeclidinium--vilanterol, vilanterol 25 µg, umeclidinium 62.5 and 125 µg, and tiotropium 18 µg.[@b23-copd-12-141],[@b41-copd-12-141] SOBDA responder rates were reported for one trial, and were significantly higher for umeclidinium--vilanterol (OR 1.8, *P*\<0.01) and its monocomponents (umeclidinium 52.5 µg OR 1.7, *P*\<0.01; vilanterol 25 µg OR 1.6, *P*\<0.05) versus placebo. In two 12-week studies, there was no significant difference in TDI focal scores between umeclidinium--vilanterol 62.5/25 µg and salmeterol--fluticasone propionate 50/250 µg.[@b27-copd-12-141] Exercise-associated dyspnea (Borg) was reduced with umeclidinium--vilanterol 62.5/25 µg compared with placebo in one of two studies; active--placebo differences were not significant for the individual components.[@b33-copd-12-141] In combined results from two 1-year studies, tiotropium--olodaterol OD increased TDI total score versus monocomponents (week 24) by approximately 0.4 points with the higher dose and by a similar margin (0.3--0.4 points) with the lower dose.[@b30-copd-12-141]

Symptoms were evaluated using a number of end points in the two 24-week aclidinium--formoterol BID studies.[@b28-copd-12-141],[@b29-copd-12-141] For TDI total score, aclidinium--formoterol 400/12 µg BID achieved a significant, \>1-point improvement versus placebo (and a higher proportion of TDI responders), but the differences versus the monotherapies were not significant. For Evaluating Respiratory Symptoms (E-RS) score, the combination was significantly better than placebo (both studies) and the monotherapies (one study). Aclidinium--formoterol 400/12 µg improved nighttime symptom scores versus placebo (one study) or aclidinium BID (one study); early morning symptom scores were improved versus placebo and aclidinium (both studies), assessed by questionnaires for both.[@b28-copd-12-141],[@b29-copd-12-141]

Rescue-medication use
---------------------

Rescue-medication usage provides a surrogate measure of symptom control, and was reported in most of the published indacaterol--glycopyrronium OD and umeclidinium--vilanterol OD Phase III trials ([Table 4](#t4-copd-12-141){ref-type="table"}). Indacaterol--glycopyrronium treatment consistently led to significantly less rescue-medication use per day than LABA or LAMA monotherapy or LABA--inhaled corticosteroids in each trial with active comparators.[@b2-copd-12-141],[@b26-copd-12-141],[@b35-copd-12-141],[@b38-copd-12-141]--[@b40-copd-12-141] In LANTERN, rescue-medication use was comparable between the indacaterol--glycopyrronium and SFC BID groups.[@b24-copd-12-141] Daily rescue-medication use was similar or numerically slightly lower with umeclidinium--vilanterol versus either umeclidinium or vilanterol monotherapy, significantly lower versus tiotropium in two of three trials, and significantly lower versus SFC in one of two trials.[@b23-copd-12-141],[@b27-copd-12-141],[@b32-copd-12-141],[@b33-copd-12-141],[@b41-copd-12-141] Rescue-medication use remained at approximately two puffs/day with tiotropium--olodaterol OD over the course of 52 weeks; at the end of the studies, this was 0.3--0.4 puffs/day less than with olodaterol and 0.7--0.8 puffs/day less than with tiotropium.[@b30-copd-12-141] In the two 24-week studies with aclidinium--formoterol 400/12 µg BID, rescue-medication use was significantly lower compared with placebo and aclidinium BID, but not compared with formoterol.[@b28-copd-12-141],[@b29-copd-12-141]

Exacerbations
-------------

The effects of FDC therapy on exacerbation rates and time to first exacerbation are summarized in [Table 5](#t5-copd-12-141){ref-type="table"}.

The effect of indacaterol--glycopyrronium OD on exacerbation rate was examined as the primary end point in both SPARK and FLAME, and exacerbation rates have also been reported from ILLUMINATE, LANTERN, and QUANTIFY.[@b24-copd-12-141]--[@b26-copd-12-141],[@b39-copd-12-141],[@b40-copd-12-141],[@b52-copd-12-141] In SPARK, indacaterol--glycopyrronium significantly reduced rates of moderate-to-severe (primary end point, rate ratio 0.88; *P*=0.038) and all exacerbations (LSM treatment difference 0.85, *P*\<0.01) versus glycopyrronium.[@b40-copd-12-141] Compared with open-label tiotropium, rates of moderate-to-severe exacerbations were 10% lower with indacaterol--glycopyrronium (*P*=0.096), and rates of all exacerbations were 14% lower (*P*\<0.01). In comparison with SFC BID in a post hoc analysis of data from ILLUMINATE, rates of moderate-to-severe exacerbations (rate ratio 0.8, not significant \[NS\]) and all exacerbations (rate ratio 0.69, NS) were numerically lower with indacaterol--glycopyrronium.[@b52-copd-12-141] In LANTERN, indacaterol--glycopyrronium significantly reduced the rate of moderate or severe exacerbations by 31% (*P*=0.048) over SFC.[@b24-copd-12-141] Furthermore, in the recent FLAME study, indacaterol--glycopyrronium significantly reduced the rates of all exacerbations (primary end point) by 11% (*P*=0.003) and of moderate-to-severe exacerbations by 17% (*P*\<0.001) compared with SFC; findings were consistently in favor of indacaterol--glycopyrronium when patients were analyzed according to their baseline disease characteristics, including baseline eosinophil count (\<2% or ≥2%).[@b26-copd-12-141] This study also found that compared with SFC, indacaterol--glycopyrronium was associated with longer times to first exacerbation, representing reduced risks of 16% for all exacerbations (*P*\<0.001), 22% for moderate-to-severe exacerbations (*P*\<0.001), and 19% for severe exacerbations (*P*=0.046). Finally, QUANTIFY showed a comparable percentage of patients experiencing at least one moderate or severe exacerbation and a comparable time to first moderate or severe exacerbation between the two treatment groups (indacaterol−glycopyrronium vs tiotropium + formoterol).[@b25-copd-12-141]

Currently, there are no studies evaluating exacerbation risk as a primary end point in patients receiving umeclidinium--vilanterol OD. The data available from analysis of secondary end points indicate that umeclidinium--vilanterol significantly increased time to first exacerbation versus placebo (HR 0.5, *P*\<0.001),[@b41-copd-12-141] but not compared with vilanterol 25 µg (HR 0.7, NS) or umeclidinium 125 µg (HR 1, NS).[@b23-copd-12-141]

Time to first exacerbation was comparable for combination therapy versus tiotropium alone in two trials[@b23-copd-12-141] and significantly greater in a third study (HR 0.5, *P*=0.044).[@b32-copd-12-141] In the combined results of the two 52-week studies with tiotropium--olodaterol OD, there was only a "trend" for improvement in exacerbations with both doses of the combination versus the monotherapy components.[@b30-copd-12-141] Over the 24 weeks of the ACLI-FORM study, using the health care resource-utilization definition of exacerbations, aclidinium--formoterol BID 400/12 µg was not significantly different from placebo or its separate components; with the EXACT (EXAcerbations of COPD Tool) definition, a significant difference was demonstrated versus placebo, but not compared with the components.[@b28-copd-12-141]

Exacerbations were not reported as an efficacy outcome in the AUGMENT study.[@b29-copd-12-141]

Health status
-------------

Indacaterol--glycopyrronium OD significantly improved health status, assessed using the SGRQ ([Table 6](#t6-copd-12-141){ref-type="table"}). In SPARK, indacaterol--glycopyrronium improved SGRQ total score versus glycopyrronium (all *P*\<0.01) and open-label tiotropium (all *P*\<0.05; 12--64 weeks).[@b40-copd-12-141] In SHINE, improvement in SGRQ with indacaterol--glycopyrronium was superior to open-label tiotropium (*P*=0.009) and placebo (*P*=0.002) and comparable to component monotherapies.[@b2-copd-12-141] In a 26-week study, indacaterol--glycopyrronium and SFC BID provided similar improvements in health status.[@b39-copd-12-141] However, in FLAME, significant improvements over time in SGRQ total score were observed for indacaterol--glycopyrronium compared with SFC, with treatment differences that ranged from −1.2 points to −1.8 points over the time points measured between weeks 12 and 52 (all *P*\<0.01).[@b26-copd-12-141] The SGRQ responder rate for the MCID (reduction of ≤4 units from baseline)[@b53-copd-12-141] was also significantly greater with indacaterol--glycopyrronium versus SFC in FLAME (OR 1.3, *P*\<0.001)[@b26-copd-12-141] and versus glycopyr-ronium (OR 1.62, *P*=0.00013) and open-label tiotropium (OR 1.48, *P*=0.0017) at all time points except week 64 in SPARK.[@b40-copd-12-141] In QUANTIFY, indacaterol--glycopyrronium was noninferior to tiotropium + formoterol for improvement in SGRQ score; the percentage of patients achieving a MCID was significantly in favor of indacaterol--glycopyrronium (50.1% vs 42.5%, *P*=0.038) in the per-protocol set.[@b25-copd-12-141] Similarly, in LANTERN comparable improvements with indacaterol--glycopyrronium versus SFC were observed for all SGRQ analyses (weeks 12 and 26).[@b24-copd-12-141]

Significant improvements in SGRQ total score mean change from baseline (*P*≤0.001) and percentages of SGRQ responders (OR 2, *P*≤0.001) were reported for umeclidinium--vilanterol 62.5/25 µg OD versus placebo in three 24-week studies.[@b41-copd-12-141] Across three of four trials, health-status improvement was not significantly different for umeclidinium--vilanterol versus monotherapy with tiotropium, vilanterol, or umeclidinium (SGRQ total scores or percentage of SGRQ responders).[@b23-copd-12-141],[@b41-copd-12-141] The fourth trial reported significant improvement in SGRQ total score from baseline (*P*\<0.006) and percentage of SGRQ responders (OR 1.4, *P*=0.022) for umeclidinium--vilanterol versus tiotropium.[@b32-copd-12-141] Improvements in SGRQ from baseline were not significantly different between umeclidinium--vilanterol 62.5/25 µg and salmeterol--fluticasone propionate 50/250 µg in two 12-week studies.[@b27-copd-12-141]

In combined results from two 1-year studies, tiotropium--olodaterol 5/5 µg OD significantly improved SGRQ total score at week 24 by 1.2 and 1.7 units versus its respective components. Proportions of SGRQ responders were significantly increased for all the combination-versus-component comparisons, apart from tiotropium--olodaterol 2.5/5 µg versus tiotropium 2.5 µg. In the 24-week ACLIFORM and AUGMENT studies, aclidinium--formoterol BID improved SGRQ total score and percentage of responders significantly compared with placebo in one study, but did not achieve significant differences against its components in either study.[@b28-copd-12-141],[@b29-copd-12-141]

Safety
------

To date, the most extensive safety data available for FDC bronchodilators comes from indacaterol--glycopyrronium OD trials. Overall, indacaterol--glycopyrronium was well tolerated across the studies, and had a similar safety profile to placebo in individual trials and analyses of pooled data.[@b2-copd-12-141],[@b36-copd-12-141],[@b39-copd-12-141],[@b40-copd-12-141],[@b54-copd-12-141]--[@b56-copd-12-141] The incidence of adverse events (AEs) and serious AEs (SAEs) reported with indacaterol--glycopyrronium treatment was comparable to that of placebo, indacaterol, glycopyrronium, tiotropium (± formoterol) or SFC BID.[@b2-copd-12-141],[@b24-copd-12-141]--[@b26-copd-12-141],[@b36-copd-12-141],[@b39-copd-12-141],[@b40-copd-12-141] Interestingly, the FLAME trial reported a significant reduction in the incidence of pneumonia with indacaterol--glycopyrronium compared with SFC (3.2% vs 4.8%, respectively; *P*=0.02).[@b26-copd-12-141] In an analysis of pooled data from 11,404 patients, the HR for indacaterol--glycopyrronium versus placebo showed no significant increase in the overall risk for death (HR \[95% CI\] 0.93 \[0.34--2.54\]), cardiocerebrovascular events (0.6 \[0.29--1.24\]), major adverse cardiovascular events (MACEs; 1.04 \[0.45--2.42\]), pneumonia (1.1 \[0.54--2.25\]), COPD exacerbations (0.6 \[0.4--0.91\]), or atrial flutter/fibrillation (1.03 \[0.49--2.18\]).[@b54-copd-12-141]

Over 24 weeks, umeclidinium--vilanterol 62.5/25 µg OD was well tolerated, and the incidence of AEs and serious AEs was similar for combination therapy versus placebo and monocomponents.[@b41-copd-12-141],[@b57-copd-12-141] The rate of class-effect AEs associated with anticholinergic (eg, dry mouth) and BA (eg, tachycardia) agents was similar to that observed for placebo.[@b41-copd-12-141],[@b57-copd-12-141] In two 12-week studies, umeclidinium--vilanterol 62.5/25 µg and SFC 250/50 µg were both well tolerated and had similar AE profiles.[@b27-copd-12-141] In a pooled analysis of data from eight trials of umeclidinium--vilanterol 62.5/25 µg and 125/25 µg, no increased risk of MACE was observed with active treatment versus placebo.[@b58-copd-12-141] Small numerical imbalances in cardiac ischemia were reported in some studies, but not others. As the imbalances were not dose-related, they were not considered drug-related. The incidence of cardiovascular AEs of special interest was comparable for umeclidinium--vilanterol, mono-components, and placebo.

In the two 1-year tiotropium--olodaterol OD studies, the frequency of AEs was largely comparable between the combination- and individual component-treatment groups. The rates of MACE and cardiac events did not differ significantly between the combination and the individual component groups.[@b30-copd-12-141] Similarly, AE reporting (including MACE and Holter monitoring) in the two aclidinium--formoterol BID studies was generally comparable across all treatment groups.[@b28-copd-12-141],[@b29-copd-12-141]

In a 2013 preliminary report from a retrospective cohort study of mortality in more than 5,000 patients with COPD, LAMA--LABA combination therapy reduced both all-cause (HR 0.53 \[95% CI 0.34--0.84\]) and cardiovascular mortality (HR 0.39 \[95% CI 0.17--0.9\]).[@b59-copd-12-141] Reductions in both mortality types were also observed with LAMA--LABA--inhaled corticosteroids, LABA--inhaled corticosteroids, and LAMA-only treatment.

Discussion
==========

We identified 23 published Phase III RCTs of FDC bronchodilators in COPD. The data demonstrated that fixed-dose LAMA--LABA combinations significantly improved lung function compared with component mono-therapies or single agents.[@b2-copd-12-141],[@b23-copd-12-141],[@b30-copd-12-141]--[@b32-copd-12-141],[@b35-copd-12-141],[@b36-copd-12-141],[@b39-copd-12-141]--[@b41-copd-12-141] Indacaterol--glycopyrronium OD, umeclidinium--vilanterol OD, and tiotropium--olodaterol OD also provided significant improvements over component monotherapies and/or tiotropium in several PROs.[@b2-copd-12-141],[@b23-copd-12-141],[@b30-copd-12-141],[@b32-copd-12-141],[@b35-copd-12-141],[@b38-copd-12-141],[@b40-copd-12-141],[@b41-copd-12-141] Compared with its components, aclidinium--formoterol BID improved symptoms (one study),[@b28-copd-12-141] but did not improve health status.[@b28-copd-12-141],[@b29-copd-12-141] Indacaterol--glycopyrronium and umeclidinium--vilanterol significantly improved lung function compared with SFC BID.[@b26-copd-12-141],[@b27-copd-12-141],[@b39-copd-12-141] Indacaterol--glycopyrronium also improved exacerbation rates in LANTERN and FLAME ([Table 6](#t6-copd-12-141){ref-type="table"}), reduced dyspnea in ILLUMINATE, and led to reductions in use of rescue medication in ILLUMINATE and FLAME compared with SFC.[@b24-copd-12-141],[@b26-copd-12-141],[@b27-copd-12-141],[@b39-copd-12-141] The safety profiles of the FDC agents were similar to placebo and incidence of pneumonia significantly reduced with indacaterol--glycopyrronium versus SFC in FLAME.[@b2-copd-12-141],[@b23-copd-12-141],[@b26-copd-12-141],[@b30-copd-12-141],[@b32-copd-12-141],[@b36-copd-12-141],[@b39-copd-12-141]--[@b41-copd-12-141],[@b54-copd-12-141],[@b56-copd-12-141]

Several studies have examined the relationship between improvements in lung function following LABA or LAMA monotherapy and improvements in other outcomes, such as SGRQ total score, TDI, exacerbation rate, and rescue-medication use. However, although significant or clinically relevant correlations appear at group levels, they tend to be only moderate, weak, or too weak to be useful at individual levels.[@b16-copd-12-141]--[@b19-copd-12-141],[@b21-copd-12-141] This may be because some patients have very poor health despite only mild lung-function impairments or vice versa.[@b17-copd-12-141] Indeed, the health impact of COPD is not necessarily mediated entirely through expiratory airflow limitation; a better correlate may instead be exercise performance.[@b17-copd-12-141] The analyzed studies may also have been too short in duration to capture meaningful changes in exacerbations or health status, and only a few studies were available for some outcomes.[@b18-copd-12-141] Finally, the Hawthorne effect may also have played a role, as changes in FEV~1~ of 0 still resulted in a 2.5-point reduction in SGRQ score in some cases.[@b18-copd-12-141]

Likewise, in trials of combination-bronchodilator therapy versus components, improvement in FEV~1~ was not always mirrored by improved PROs. For example, significant improvement in dyspnea for umeclidinium--vilanterol OD versus monocomponents occurred only for vilanterol (in one of three trials), despite improvements in FEV~1~.[@b23-copd-12-141],[@b41-copd-12-141] Possible reasons for this include insufficient sensitivity/specificity in instruments assessing PROs. Additionally, such measurements as inspiratory capacity may be more strongly related to dyspnea and COPD pathophysiology than FEV~1~.[@b60-copd-12-141] Therefore, it may be useful to examine correlations between other outcomes instead, in larger sample sizes or longer-duration studies. Findings may still be somewhat limited though, as these end points are often only secondary, meaning power may be lacking.

Patient-selection criteria represent an important limitation of RCTs. Most trials recruit subjects from highly selective populations likely to represent less than 5% of "real-life" patients. As such, the extrapolation of RCT data is limited.[@b61-copd-12-141] Populations are generally chosen to demonstrate the primary end point (usually lung function). Clinical trial participants tend to be less symptomatic than general patient populations, and clinical trials may exclude patients likely to benefit the most from treatment (as a maximum level of benefit may be reached sooner). Additionally, the most symptomatic patients in control arms may discontinue study treatment to obtain greater symptom relief. In contrast, real-life studies are likely to involve broader populations and treat each study arm to a similar level. Roche et al suggested a new framework to categorize the approach taken in clinical trials from highly controlled efficacy RCT management to usual clinical care.[@b61-copd-12-141] The positioning of studies on this scale can be useful as a descriptive classification.[@b61-copd-12-141] Future COPD trials may need to include more real-life patient populations and ecology of care. In addition, composite end points, such as lack of exacerbations and improved health status, may provide greater insight into the true benefits of treatment.

Additional studies of fixed-combination bronchodilators are needed to characterize further the relationship between FEV~1~ and PROs with these agents, as well as defining optimal strategies for their use in clinical practice. Should therapy be initiated with a single bronchodilator and then stepped up to a LABA--LAMA combination and/or triple therapy with LABA--LAMA plus another agent as needed, or should treatment commence with a LABA--LAMA in certain patients?

In conclusion, our review of a systematic literature search indicates that fixed-dose LABA--LAMA combinations significantly improved lung function compared with their component monotherapies. In general, LABA--LAMA combinations also improved other outcomes, including symptoms and health status, compared with the monotherapies, although some discrepancies between lung function and PROs were apparent. Further research is needed to explore the relationship between lung-function outcomes and PROs in patients receiving LABA--LAMA combinations.

Supplementary materials
=======================

###### 

Search strategy and results for published manuscripts and congress abstracts

  Search number   Search terms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Number of records
  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  S1              MeSH.EXACT.EXPLODE ("Bronchodilator Agents") AND MeSH.EXACT.EXPLODE ("Drug Combinations")                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                821[a](#tfn41-copd-12-141){ref-type="table-fn"}
  S2              "Fixed-dose combination" OR "Fixed dose combination" OR "Fixed-dose long-acting combination" OR "Fixed dose long-acting combination" OR "Fixed-dose combinations" OR "Fixed dose combinations" OR "Fixed-dose long-acting combinations" OR "Fixed dose long-acting combinations" OR "fixed combination" OR "fixed combinations" OR "LABA/LAMA" OR "LAMA/LABA" OR "dual bronchodilator" OR "dual bronchodilators" OR "dual bronchodilation" OR "dual-acting bronchodilator" OR "dual-acting bronchodilators" OR "dual-acting bronchodilation" OR "QVA149" OR "QVA-149" OR "QVA 149" OR "glycopyrronium/indacaterol" OR "indacaterol/glycopyrronium" OR "Anoro" OR "umeclidinium/vilanterol" OR Embase.EXACT ("glycopyrronium bromide plus indacaterol")   6,959[b](#tfn42-copd-12-141){ref-type="table-fn"}
  S3              MeSH.EXACT.EXPLODE ("Pulmonary Disease, Chronic Obstructive") OR "chronic obstructive pulmonary disease" OR "COPD" OR "Chronic Obstructive Lung Disease" OR "Chronic Obstructive Airway Disease"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         90,402[b](#tfn42-copd-12-141){ref-type="table-fn"}
  S4              (S1 OR S2) AND S3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        444[a](#tfn41-copd-12-141){ref-type="table-fn"}

**Notes:**

Duplicate citations removed from result count

result count includes duplicate citations. ProQuest search, including Biosis, Biosis previews, Embase, and Medline databases. Searches were limited to publications from January 1, 2006 to July 31, 2014 and English-language articles.

**Abbreviations:** EXACT, EXAcerbations of COPD Tool; EXPLODE, terms indexed as subterms included; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; MeSH, Medical Subject Headings.

###### 

Congress abstract search strategy and results

  ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Congress abstracts searched   • Annual Congress of the European Respiratory Society\
                                • Annual International Conference of the American Thoracic Society\
                                • Annual Winter Meeting of the British Thoracic Society\
                                • Biennial International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease\
                                • Biennial World Conference of the International Primary Care Respiratory Group\
                                • CHEST\
                                • Annual Congress of the Asian Pacific Society of Respirology

  Search terms                  "Fixed-dose combination" OR "Fixed dose combination" OR "Fixed-dose long-acting combination" OR "Fixed dose long-acting combination" OR "Fixed-dose combinations" OR "Fixed dose combinations" OR "Fixed-dose long-acting combinations" OR "Fixed dose long-acting combinations" OR "fixed combination" OR "fixed combinations" OR "LABA/LAMA" OR "LAMA/LABA" OR "dual bronchodilator" OR "dual-bronchodilator" OR "dual-bronchodilators" OR "dual-bronchodilation" OR "dual bronchodilators" OR "dual bronchodilation" OR "dual-acting bronchodilator" OR "dual-acting bronchodilators" OR "dual-acting bronchodilation" OR "dual acting bronchodilator" OR "dual acting bronchodilators" OR "dual acting bronchodilation" OR "QVA149" OR "QVA-149" OR "QVA 149" OR "glycopyrronium/indacaterol" OR "indacaterol/glycopyrronium" OR "Anoro" OR "umeclidinium/vilanterol" OR "glycopyrronium bromide plus indacaterol" OR "glycopyrronium plus indacaterol"

  Number of records             285
  ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Available abstracts from January 1, 2009 to May 20, 2015 were included in the literature search.
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![Flowchart of systematic literature search.\
**Notes:** Reasons for exclusion comprised: not a primary publication or not containing novel data from clinical studies, non-COPD study, data not from a randomized clinical study, medication not combination LABA--LAMA bronchodilator treatment, and unapproved dose for a licensed combination therapy.\
**Abbreviations:** LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist.](copd-12-141Fig1){#f1-copd-12-141}

![Differences between monotherapy and combination bronchodilators or placebo in TDI patient-response rates in published studies.\
**Notes:** (**A**) Indacaterol--glycopyrronium; (**B**) umeclidinium--vilanterol 62.5/25 µg; (**C**) aclidinium--formoterol 400/12 µg BID. TDI response was defined as improvement of ≥1 unit in TDI score. All treatments were once daily unless stated otherwise. \*Significant treatment difference. ^a^Bateman et al;[@b2-copd-12-141] ^b^self-administered computerized TDI;[@b38-copd-12-141] ^c^Vogelmeier et al;[@b39-copd-12-141] ^d^Buhl et al;[@b25-copd-12-141] ^e^Donohue et al;[@b41-copd-12-141] ^f^Decramer et al;[@b23-copd-12-141] ^g^Singh et al;[@b28-copd-12-141] ^h^D'Urzo et al.[@b29-copd-12-141]\
**Abbreviations:** BID, bis in die (twice daily); SFC, salmeterol--fluticasone propionate; TDI, transition dyspnea index.](copd-12-141Fig2){#f2-copd-12-141}

###### 

Clinical trials of FDC bronchodilator therapies evaluating treatment effects on lung function and/or patient-reported outcome

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference and study                     Design              Duration        Patients, n[a](#tfn2-copd-12-141){ref-type="table-fn"}   Patient population                                                                                                                                                                                                                                                                                                                   Mean FEV~1~% predicted (GOLD stage)   Treatment                                                                                           Primary and other efficacy outcomes
  --------------------------------------- ------------------- --------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Published Phase III clinical trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **IND--GLY**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Bateman et al[@b2-copd-12-141]\         MC, R, DB           26 weeks        2,144                                                    Moderate-to-severe COPD (FEV~1~ ≥30% and \<80% predicted) and symptomatic (total daily symptom score ≥1 on ≥4 of the 7 days prior to randomization); 75% had no reports of exacerbations in the previous year                                                                                                                        55 (II or III)                        IND--GLY 110/50 µg Indacaterol 150 µg Glycopyrronium 50 µg Tiotropium 18 µg OL Placebo              Trough FEV~1~ at week 26 (primary) Dyspnea (TDI) Health status (SGRQ) Rescue-medication use Symptoms (diary)
  (SHINE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Dahl et al[@b36-copd-12-141]\           MC, R, DB           52 weeks        339                                                      Moderate-to-severe COPD (FEV~1~ ≥30% and \<80% predicted) and symptomatic (total daily symptom score ≥1 on ≥4 of the 7 days prior to randomization); excluded patients who had an exacerbation requiring antibiotics, oral steroids, or hospitalization, within ≤6 weeks prior to screening or between screening and randomization   57 (II or III)                        IND--GLY 110/50 µg Placebo                                                                          Safety (primary) Rescue-medication use Symptoms (diary) Trough FEV~1~
  (ENLIGHTEN)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Dahl et al[@b37-copd-12-141]\           MC, R, DB           4 weeks         193                                                      Moderate-to-severe COPD (FEV~1~ ≥30% and \<80% predicted) and symptomatic (total daily symptom score ≥1 on ≥3 days prior to randomization); excluded patients who had an exacerbation requiring treatment with antibiotics and/or oral corticosteroids and/or hospitalization ≤6 weeks prior to visit 1                              54 (II or III)                        IND--GLY 110/50 µg Indacaterol 150 µg + glycopyrronium 50 µg                                        Trough FEV~1~ at week 4 (noninferiority; primary) Rescue-medication use Symptoms (diary)
  (BEACON)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Mahler et al[@b38-copd-12-141]\         MC, R, B, DD, XO    6 weeks         247                                                      Moderate-to-severe COPD (FEV~1~ ≥30% and \<80% predicted) with mMRC grade ≥2; 70% of patients had no history of exacerbations in the previous year                                                                                                                                                                                   56 (II or III)                        IND--GLY 110/50 µg Placebo Tiotropium 18 µg                                                         Dyspnea at week 6 (TDI-SAC; primary) FEV~1~ AUC~0--4\ h~ Rescue-medication use Symptoms (diary)
  (BLAZE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Vogelmeier et al[@b39-copd-12-141]\     MC, R, DB, DD       26 weeks        523                                                      Moderate-to-severe COPD (FEV~1~ ≥40% and \<80% predicted) and symptomatic (total daily symptom score ≥1 on ≥4 of the 7 days prior to randomization); excluded patients with exacerbations requiring treatment with antibiotics, systemic corticosteroids, and/or hospitalization in the previous year                                60 (II or III)                        IND--GLY 110/50 µg SFC 50/500 µg BID                                                                FEV~1~ AUC~0--12\ h~ at week 26 (primary) Dyspnea (TDI) FEV~1~ and FVC Health status (SGRQ) Rescue-medication use Symptoms (diary)
  (ILLUMINATE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Wedzicha et al[@b40-copd-12-141]\       MC, R, DB           64 weeks        2,224                                                    Severe-to-very-severe COPD (FEV~1~ \<50% predicted) with ≥1 COPD exacerbation requiring treatment with systemic corticosteroids and/or antibiotics in the previous year                                                                                                                                                              37 (III or IV)                        IND--GLY 110/50 µg Glycopyrronium 50 µg Tiotropium 18 µg OL                                         Exacerbations (primary) Health status (SGRQ) Rescue-medication use Trough FEV~1~
  (SPARK)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Beeh et al[@b35-copd-12-141]\           MC, R, DB, DD, XO   3 weeks         85                                                       Moderate-to-severe COPD (FEV~1~ ≥40% and \<70% predicted); 83% of patients had no history of exacerbation in the previous year                                                                                                                                                                                                       56 (II or III)                        IND--GLY 110/50 µg Tiotropium 18 µg[b](#tfn3-copd-12-141){ref-type="table-fn"} Placebo              Exercise endurance time at week 3 (primary) Dyspnea and leg discomfort (Borg) Lung function Rescue-medication use Symptoms (diary)
  (BRIGHT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Buhl et al[@b25-copd-12-141]\           DB, TD              26 weeks        934                                                      Moderate-to-severe COPD (FEV~1~ ≥30%--\<80% predicted; postbronchodilator FEV~1~ to FVC ratio \<0.7 at screening), current or ex-smoker (≥10 pack-years); no COPD exacerbation within 6 weeks of prescreening or prior to randomization                                                                                              53 (II or III)                        IND--GLY 110/50 µg Tiotropium 18 µg + formoterol 12 µg BID                                          Health status (SGRQ-C; primary) Dyspnea (TDI) Symptoms (SGRQ-C) FEV~1~ and FVC Exacerbations
  (QUANTIFY)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Zhong et al[@b24-copd-12-141]\          MC, R, DB, DD       26 weeks        744                                                      Moderate-to-severe COPD (FEV~1~ ≥30%--\<80% predicted; postbronchodilator FEV~1~to FVC ratio \<0.7 at screening), current or ex-smoker (≥10 pack-years); mMRC grade ≥2; ≤1 COPD exacerbation within 12 months of screening/randomization                                                                                             52 (II or III)                        IND--GLY 110/50 µg SFC 50/500 µg BID                                                                Trough FEV~1~ at week 26 (primary) Other FEV~1~, FVC Dyspnea (TDI) Health status (SGRQ and CAT) Rescue-medication use Symptoms (diary) Exacerbations
  (LANTERN)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Wedzicha et al[@b26-copd-12-141]\       MC, R, DB, DD, NI   52 weeks        3,362                                                    Moderate-to-very-severe COPD (FEV~1~ ≥25%--\<60% predicted; postbronchodilator FEV~1~ to FVC ratio \<0.7 at screening); mMRC grade ≥2; a documented history of ≥1 COPD exacerbation requiring treatment with systemic corticosteroids and/or antibiotics) in the previous 1 year                                                     44 (II--IV)                           IND--GLY 110/50 µg\                                                                                 Exacerbations (primary)\
  (FLAME)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         SFC 50/500 µg BID                                                                                   Other exacerbation end points\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Trough FEV~1~ and FEV~1~\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      AUC~0--12\ h~\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Health status (SGRQ-C)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rescue-medication use

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **UMEC--VI**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Donohue et al[@b41-copd-12-141]         MC, R, DB           24 weeks        1,536                                                    Moderate-to-very-severe COPD (FEV~1~ ≤70% predicted) and mMRC grade ≥2; exacerbation history not stated                                                                                                                                                                                                                              47 (II--IV)                           UMEC--VI 62.5/25 µgUmeclidinium 62.5 µg\                                                            Trough FEV~1~ at week 24 (primary)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Vilanterol 25 µg\                                                                                   Dyspnea (TDI, SOBDA)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Placebo                                                                                             Exacerbations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Other FEV~1~, FVC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Health status (SGRQ)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rescue-medication use

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Decramer et al[@b23-copd-12-141]\       MC, R, B, DD        24 weeks        843                                                      Moderate-to-very-severe COPD (FEV~1~ ≤70% predicted) and mMRC grade ≥2; 53% of patients experienced an exacerbation in the previous year                                                                                                                                                                                             48 (II--IV)                           UMEC--VI 125/25 µg\                                                                                 Trough FEV~1~ at week 24 (primary)\
  (study 1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       UMEC--VI 62.5/25 µg\                                                                                Dyspnea (TDI, SOBDA)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Tiotropium 18 µg\                                                                                   Exacerbations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Vilanterol 25 µg                                                                                    Health status (SGRQ)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Other FEV~1~, FVC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rescue-medication use

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Decramer et al[@b23-copd-12-141]\       MC, R, B, DD        24 weeks        869                                                      Moderate-to-very-severe COPD (FEV~1~ ≤70% predicted) and mMRC grade ≥2; 38% of patients had experienced an exacerbation in the previous year                                                                                                                                                                                         47 (II--IV)                           UMEC--VI 125/25 µg\                                                                                 Trough FEV~1~ at week 24 (primary)\
  (study 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       UMEC--VI 62.5/25 µg\                                                                                Dyspnea (TDI, SOBDA)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Tiotropium 18 µg\                                                                                   Exacerbations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Umeclidinium 125 µg                                                                                 Health status (SGRQ)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Other FEV~1~, FVC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rescue-medication use

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Maleki-Yazdiet al[@b32-copd-12-141]     MC, R, B, DD        24 weeks        905                                                      Moderate-to-very-severe COPD (FEV~1~ ≤70% predicted) and mMRC grade ≥2; exacerbation history not stated                                                                                                                                                                                                                              46 (II--IV)                           UMEC--VI 62.5/25 µg\                                                                                Trough FEV~1~ at week 24 (primary)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Tiotropium 18 µg                                                                                    Exacerbations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Health status (SGRQ)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Other FEV~1~, FVC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rescue-medication use

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Maltais et al[@b33-copd-12-141]\        MC, R, DB, XO       12 weeks        349                                                      Moderate-to-severe COPD (FEV~1~ ≥35% and ≤70% predicted), mMRC grade ≥2 and FRC ≥120% (hyperinflated); exacerbation history not stated                                                                                                                                                                                               51 (II or III)                        UMEC--VI 125/25 or 62.5/25 µg\                                                                      Exercise-endurance time at week 12 (co-primary)\
  (study 1 \[417\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Umeclidinium 62.5 or 125 µg\                                                                        Trough FEV~1~ at week 12 (co-primary)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Vilanterol 25 µg\                                                                                   Lung function\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Placebo                                                                                             Lung volume

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Maltais et al[@b33-copd-12-141]\        MC, R, DB, XO       12 weeks        308                                                      Moderate-to-severe COPD (FEV~1~ ≥35% and ≤70% predicted), mMRC grade ≥2 and FRC ≥120% (hyperinflated); exacerbation history not stated                                                                                                                                                                                               51 (II or III)                        UMEC--VI 125/25 or 62.5/25 µg\                                                                      Exercise-endurance time at week 12 (coprimary)\
  (study 2 \[418\])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Umeclidinium 62.5 or 125 µg\                                                                        Trough FEV~1~ at week 12 (coprimary)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Vilanterol 25 µg\                                                                                   Lung function\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Placebo                                                                                             Lung volume

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Donohue et al[@b27-copd-12-141]\        MC, R, DB, DD       12 weeks        707                                                      Moderate-to-severe COPD; (FEV~1~ ≥30% and ≤70% predicted); no exacerbations in past year                                                                                                                                                                                                                                             49--50 (II or III)                    UMEC--VI 62.5/25 µg\                                                                                FEV~1~ 0--24 hours at week 12 (primary)\
  (study 2114930)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 SFC 50/250 µg                                                                                       Other FEV~1~, FVC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      IC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Dyspnea (TDI)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Health status (EuroQol 5D, SGRQ, and CAT)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rescue-medication use\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Symptoms (diary)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Donohue et al[@b27-copd-12-141]\        MC, R, DB, DD       12 weeks        700                                                      Moderate-to-severe COPD; (FEV~1~ ≥30% and ≤70% predicted); no exacerbations in past year                                                                                                                                                                                                                                             49--50 (II or III)                    UMEC--VI 62.5/25 µg\                                                                                FEV~1~ 0--24 hours at week 12 (primary)\
  (study 2114951)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 SFC 50/250 µg                                                                                       Other FEV~1~, FVC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Dyspnea (TDI)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Health status (EuroQol 5D, SGRQ, and CAT)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Rescue-medication use\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Symptoms (diary)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **TIO--OLO**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Buhl et al[@b30-copd-12-141]\           MC, R, DB           52 weeks (×2)   2,624                                                    Moderate-to-severe COPD (GOLD stage II--III); FEV~1~ ≥30% and \<80% predicted; exacerbation history not stated                                                                                                                                                                                                                       49--50 (I--IV)                        Olodaterol 5 µg\                                                                                    FEV~1~ 0--3 hours, trough FEV~1~ and health status (SGRQ total score) at week 24 (joint primary)\
  (replicate studies 1237.5 and 1237.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Tiotropium 2.5 µg\                                                                                  Dyspnea (TDI)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Tiotropium 5 µg\                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  TIO--OLO 2.5/5 µg\                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  TIO--OLO 5/5 µg                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Beeh et al[@b31-copd-12-141]\           MC, R, DB, IN, XO   6 weeks         219                                                      Moderate-to-very-severe COPD (GOLD stage II--IV); FEV~1~ \<80% predicted (≥30% for certain sites); exacerbation history not stated                                                                                                                                                                                                                                         Olodaterol 5 µg\                                                                                    FEV~1~ AUC~0--24\ h~ at week 6 (primary)\
  (VIVACITO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Tiotropium 2.5 µg\                                                                                  Other FEV~1~, FVC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Tiotropium 5 µg\                                                                                    FRC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  TIO--OLO 2.5/5 µg\                                                                                  Residual volume
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  TIO--OLO 5/5 µg\                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Placebo                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **ACL--FORM**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Singh et al[@b28-copd-12-141]\          MC, R, DB           24 weeks        1,729                                                    Moderate-to-severe COPD (FEV~1~ ≥30%, but \<80% predicted); exacerbation history not stated                                                                                                                                                                                                                                          54 (III--IV)                          Placebo ACL--FORM 400/12 µg BID ACL--FORM 400/6 µg BID Aclidinium 400 µg BID Formoterol 12 µg BID   FEV~1~ 1 hour postdose (co-primary)\
  (ACLIFORM-COPD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Trough FEV~1~ (co-primary)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Dyspnea (TDI)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Symptoms (diary)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Daytime symptoms (EXACT)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Respiratory symptoms (E-RS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Night and early morning\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      symptoms (questionnaire)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Exacerbations (HCRU)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  D'Urzo et al[@b29-copd-12-141]\         MC, R, DB           24 weeks        1,692                                                    Moderate-to-severe COPD (FEV~1~ ≥30% and \<80% predicted); excluded patients with exacerbations ≤6 weeks (≤3 months if hospitalized for exacerbation) before screening                                                                                                                                                               53--55 (III--IV)                      Placebo\                                                                                            FEV~1~ hour postdose (coprimary)\
  (AUGMENT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ACL--FORM\                                                                                          Trough FEV~1~ (coprimary)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  400/12 µg BID\                                                                                      Dyspnea (TDI)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ACL--FORM\                                                                                          Health status (SGRQ)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  400/6 µg BID\                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Aclidinium 400 µg BID\                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Formoterol 12 µg BID                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference and study                     Design                Duration   Patients, n[a](#tfn2-copd-12-141){ref-type="table-fn"}   Mean FEV~1~% predicted (GOLD stage)                  Treatment                Primary and other efficacy outcomes
  --------------------------------------- --------------------- ---------- -------------------------------------------------------- ---------------------------------------------------- ------------------------ ------------------------------------------------------------
  **Studies reported in abstract form**                                                                                                                                                                           

                                                                                                                                                                                                                  

  **IND--GLY**                                                                                                                                                                                                    

  Asai et al[@b62-copd-12-141]\           MC, R, OL             52 weeks   160                                                      NR (II or III)                                       IND--GLY 110/50 µg\      Safety (primary)\
  (ARISE)                                                                                                                                                                                Tiotropium 18 µg OL      Lung function\
                                                                                                                                                                                                                  Health status (SGRQ)\
                                                                                                                                                                                                                  Symptoms (diary)

                                                                                                                                                                                                                  

  **UMEC--VI**                                                                                                                                                                                                    

  Donohue et al[@b42-copd-12-141]\        MC, R, DB, XO         12 weeks   207                                                      NR (NR)[c](#tfn4-copd-12-141){ref-type="table-fn"}   UMEC--VI 62.5/25 µg\     FEV~1~ at week 2
  (study 1)                                                                                                                                                                              Umeclidinium 62.5 µg\    
                                                                                                                                                                                         Vilanterol 25 µg         

                                                                                                                                                                                                                  

  Donohue et al[@b42-copd-12-141]\        MC, R, DB, XO         12 weeks   182                                                      NR (NR)[c](#tfn4-copd-12-141){ref-type="table-fn"}   UMEC--VI 62.5/25 µg\     FEV~1~ at week 12
  (study 2)                                                                                                                                                                              Umeclidinium 62.5 µg\    
                                                                                                                                                                                         Vilanterol 25 µg         

                                                                                                                                                                                                                  

  Singh et al[@b43-copd-12-141]           MC, R, DB, DD         12 weeks   716                                                      NR (II or III)                                       UMEC--VI 62.5/25 µg\     FEV~1~ at week 12 (primary)\
                                                                                                                                                                                         SFC 500/50 µg BID        Dyspnea (TDI)\
                                                                                                                                                                                                                  Health status (SGRQ)

                                                                                                                                                                                                                  

  **TIO-OLO**                                                                                                                                                                                                     

  Maltais et al[@b45-copd-12-141]\        DB, PG                12 weeks   404                                                      NR (II--III)                                         TIO--OLO 5/5 µg\         Exercise-endurance time at week 12
  (TORRACTO)                                                                                                                                                                             TIO--OLO 2.5/5 µg        

  O'Donnell et al[@b34-copd-12-141]\      DB, PG, IN, XO        6 weeks    586                                                      58.6 (II--III)                                       TIO--OLO 5/5 µg\         IC at rest (coprimary)\
  (MORACTO 1 and 2)                                                                                                                                                                      TIO--OLO 2.5/5 µg\       Exercise endurance (coprimary)\
                                                                                                                                                                                         Tiotropium 5 µg\         Breathing discomfort during exercise testing
                                                                                                                                                                                         Olodaterol 5 µg\         
                                                                                                                                                                                         Placebo                  

                                                                                                                                                                                                                  

  **ACL--FORM**                                                                                                                                                                                                   

  D'Urzo et al[@b63-copd-12-141]\         R, DB, AC extension   52 weeks   1,668                                                    NR (NR)                                              ACL--FORM\               Postdose and trough FEV~1~\
  (AUGMENT extension)                                                                                                                                                                    400/12 µg BID\           Dyspnea (TDI) and responders
                                                                                                                                                                                         ACL--FORM\               
                                                                                                                                                                                         400/6 µg BID\            
                                                                                                                                                                                         Aclidinium 400 µg BID\   
                                                                                                                                                                                         Formoterol 12 µg BID\    
                                                                                                                                                                                         Placebo                  

                                                                                                                                                                                                                  

  Donohue et al[@b46-copd-12-141]         R, DB, PG             52 weeks   581                                                      NR (II--III)                                         ACL--FORM\               Trough FEV~1~\
                                                                                                                                                                                         400/12 µg BID\           Rescue-medication use\
                                                                                                                                                                                         Formoterol 12 µg BID     Safety

                                                                                                                                                                                                                  

  Vogelmeier et al[@b47-copd-12-141]      R, DB, DD, AC         24 weeks   933                                                      53.2 (NR)                                            ACL--FORM\               Peak FEV~1~ at week 24 (primary)\
                                                                                                                                                                                         400/12 µg BID\           Peak FEV~1~ at other visits, TDI, CAT score, exacerbations
                                                                                                                                                                                         SFC 50/500 µg            

                                                                                                                                                                                                                  

  **GFF**                                                                                                                                                                                                         

                                                                                                                                                                                                                  

  Reisner et al[@b48-copd-12-141]         R, DB, XO\            7 days     118                                                      NR (II--IV)                                          GFF 72/9.6 µg BID\       Trough FEV~1~\
                                          Phase IIB                                                                                                                                      GFF 36/9.6 µg BID\       IC
                                                                                                                                                                                         Tiotropium 18 µg BID\    
                                                                                                                                                                                         Placebo                  

                                                                                                                                                                                                                  

  Reisner et al[@b49-copd-12-141]         R, DB, XO\            7 days     NR                                                       NR (II--IV)                                          GFF 72/9.6 µg BID\       Lung function\
                                          Phase IIB                                                                                                                                      GFF 36/9.6 µg BID\       Mean PEFR\
                                                                                                                                                                                         Glycopyrrolate MDI\      Rescue use
                                                                                                                                                                                         36 µg BID\               
                                                                                                                                                                                         Formoterol MDI\          
                                                                                                                                                                                         9.6 µg BID\              
                                                                                                                                                                                         Formoterol MDI\          
                                                                                                                                                                                         7.2 µg BID\              
                                                                                                                                                                                         Tiotropium 18 µg\        
                                                                                                                                                                                         Formoterol DPI\          
                                                                                                                                                                                         12 µg BID\               
                                                                                                                                                                                         Placebo                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Treatment was once daily unless stated otherwise.

Patients randomized to treatment;

investigator-blinded only;

inclusion criteria: FEV~1~ ≤70% predicted and FEV~1~/FVC 0.7.

**Abbreviations:** ACL--FORM, aclidinium--formoterol; AUC~0--4\ h~, area under the (plasma concentration--time) curve from 0 to 4 hours; AUC0--12 h, area under the (plasma concentration--time) curve from 0 to 12 hours; AUC0--24 h, area under the (plasma concentration--time) curve from 0 to 24 hours; B, blinded; BID, bis in die (twice daily); CAT, COPD Assessment Test; DB, double-blind; DD, double-dummy; DPI, dry-powder inhaler; E-RS, Evaluating Respiratory Symptoms; EXACT, EXAcerbations of COPD Tool; FEV~1~, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; GFF, glycopyrrolate--formoterol fumarate; GOLD, Global Initiative For Chronic Obstructive Lung Disease; HCRU, health care-resource utilization; IC, inspiratory capacity; IN, incomplete; IND--GLY, indacaterol--glycopyrronium; MC, multicenter; MDI, metered-dose inhaler; mMRC, modified Medical Research Council; NI, noninferiority; NR, not reported; OL, open-label; PEFR, peak expiratory flow rate; R, randomized; SFC, salmeterol--fluticasone combination; SOBDA, Shortness Of Breath with Daily Activity; SGRQ-C, St George's Respiratory Questionnaire -- COPD; TD, triple-dummy; TDI-SAC, transition dyspnea index -- self-administered, computerized; TIO--OLO, tiotropium--olodaterol; UMEC--VI, umeclidinium--vilanterol; XO, crossover.

###### 

Lung function: margin of efficacy of fixed combinations versus comparators in fully published studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference and study                                                                                       Duration   Treatment                                                                                         Trough FEV~1~ LSM (95% CI) treatment difference at end point, mL   Other lung-function parameters
  --------------------------------------------------------------------------------------------------------- ---------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **IND--GLY**                                                                                                                                                                                                                                                                              

  Bateman et al[@b2-copd-12-141] (SHINE)                                                                    26 weeks   IND--GLY 110/50 µg OD vs Indacaterol 150 µg OD\                                                                                                                      IND--GLY provided significantly higher FEV~1~ AUC0--4 h and peak FEV~1~ compared with placebo, glycopyrronium, and tiotropium (all *P*\<0.01)
                                                                                                                       Glycopyrronium 50 µg OD\                                                                                                                                             
                                                                                                                       Tiotropium 18 µg OD OL\                                                                                                                                              
                                                                                                                       Placebo                                                                                                                                                              

  70[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                        

  80[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                        

  70[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                        

  200[a](#tfn7-copd-12-141){ref-type="table-fn"} (170--240)                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                            

  Dahl et al[@b36-copd-12-141] (ENLIGHTEN)                                                                  52 weeks   IND--GLY 110/50 µg OD vs placebo                                                                                                                                     FEV~1~ at 60 minutes postdose significantly greater with IND--GLY than placebo throughout the 52-week treatment period (*P*\<0.001 at all time points); IND--GLY improved FVC versus placebo over the 52-week treatment period (*P*\<0.001 at all time points)

  189[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                            

  Dahl et al[@b37-copd-12-141] (BEACON)                                                                     4 weeks    IND--GLY 110/50 µg OD vs indacaterol 150 µg OD + glycopyrronium 50 µg OD                                                                                             FEV~1~ AUC~0--4\ h~ (day 1 and week 4) similar between treatment groups

  5 (NR; NS for superiority)                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                            

  Mahler et al[@b38-copd-12-141] (BLAZE)                                                                    6 weeks    IND--GLY 110/50 µg OD vs Placebo\                                                                                                                                    FEV~1~ AUC0--4 h postdose significantly higher for IND--GLY vs tiotropium and placebo at day 1 and week 6 (all *P*\<0.001)
                                                                                                                       Tiotropium 18 µg OD                                                                                                                                                  

  330 (0.31--0.36)[a](#tfn7-copd-12-141){ref-type="table-fn"},[b](#tfn8-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                   

  110 (0.08--0.13)[a](#tfn7-copd-12-141){ref-type="table-fn"},[b](#tfn8-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                            

  Vogelmeier et al[@b39-copd-12-141] (ILLUMINATE)                                                           26 weeks   IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                                                                                           Week 26 FEV~1~ AUC0--12 h significantly higher with IND--GLY than with SFC (treatment difference 138 mL, 95% CI 0.1--0.176; *P*\<0.0001)

  103[a](#tfn7-copd-12-141){ref-type="table-fn"} (65--141)                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                            

  Wedzicha et al[@b40-copd-12-141] (SPARK)                                                                  64 weeks   IND--GLY 110/50 µg OD vs Glycopyrronium 50 µg OD\                                                 Weeks 4--64:                                                       NR
                                                                                                                       Tiotropium 18 µg OD OL                                                                                                                                               

  70--80[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                    

  60--80[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                            

  Beeh et al[@b35-copd-12-141] (BRIGHT)                                                                     3 weeks    IND--GLY 110/50 µg OD vs Tiotropium 18 µg OD[a](#tfn7-copd-12-141){ref-type="table-fn"} Placebo                                                                      At day 21, mean treatment differences in trough IC, FEV~1~, and FVC significantly higher for IND--GLY vs placebo (190, 200, and 280 mL, respectively) and vs tiotropium (150, 100, and 110 mL, respectively)

  100[a](#tfn7-copd-12-141){ref-type="table-fn"} (50--150)                                                                                                                                                                                                                                  

  200[a](#tfn7-copd-12-141){ref-type="table-fn"} (150--260)                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                            

  Buhl et al[@b25-copd-12-141] (QUANTIFY)                                                                   26 weeks   IND/GLY 110/50 µg OD vs tiotropium 18 µg OD + formoterol 12 µg BID                                                                                                   IND--GLY increased predose FVC vs tiotropium + formoterol at week 26 (74 mL, 95% CI: 24--125 mL; *P*=0.004)

  68[a](#tfn7-copd-12-141){ref-type="table-fn"} (37--100)                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                            

  Zhong et al[@b24-copd-12-141]\                                                                            26 weeks   IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                                                                                           Improvements in trough FEV~1~ with IND--GLY vs SFC observed at day 1 (Δ=43 mL) and reaching steady state by week 12 (Δ=78 mL, both *P*\<0.001).\
  (LANTERN)                                                                                                                                                                                                                                                                                 Improvements in FEV~1~ AUC~0--4\ h~ at day 1/week 26 with IND--GLY vs SFC (Δ=65/122 mL, respectively). Peak FEV~1~ higher at day 1/week 26 with IND--GLY vs SFC (*P*\<0.001). Trough FVC higher for IND--GLY vs SFC (*P*\<0.001).\
                                                                                                                                                                                                                                                                                            Improvements in peak FVC (over the first 4 hours) with IND--GLY vs SFC at day 1/week 26 (all *P*\<0.001)

  72[a](#tfn7-copd-12-141){ref-type="table-fn"} (40--104)                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                            

  Wedzicha et al[@b26-copd-12-141]\                                                                         52 weeks   IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                                                                                           Change from baseline in FEV~1~ AUC~0--12h~ (measured in a subgroup of 556 patients) was significantly greater with IND--GLY vs SFC at week 52 (Δ=110 mL, *P*\<0.001)
  (FLAME)                                                                                                                                                                                                                                                                                   

  62[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                            

  **UMEC--VI**                                                                                                                                                                                                                                                                              

  Donohue et al[@b41-copd-12-141]                                                                           24 weeks   UMEC--VI 62.5/25 µg OD vs Umeclidinium 62.5 µg OD\                                                Change from baseline:                                              Improvements in trough FVC change from baseline observed at day 169 for UMEC--VI 62.5/25 µg, UMEC 62.5 µg, and VI 25 µg vs placebo (248 mL, 175 mL, and 105 mL; all *P*\<0.002)
                                                                                                                       Vilanterol 25 µg OD\                                                                                                                                                 
                                                                                                                       Placebo                                                                                                                                                              

  52[a](#tfn7-copd-12-141){ref-type="table-fn"} (17--87)                                                                                                                                                                                                                                    

  95[a](#tfn7-copd-12-141){ref-type="table-fn"} (60--130)                                                                                                                                                                                                                                   

  167[a](#tfn7-copd-12-141){ref-type="table-fn"} (128--207)                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                            

  Decramer et al[@b23-copd-12-141] (study 1)                                                                24 weeks   UMEC--VI 125/25 µg OD[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                 Change from baseline:                                              Mean 0- to 6-hour FEV~1~ on day 168 for UMEC--VI (both doses) significantly improved vs tiotropium 18 µg
                                                                                                                       UMEC--VI 62.5/25 µg OD vs Tiotropium 18 µg OD\                                                                                                                       
                                                                                                                       Vilanterol 25 µg OD                                                                                                                                                  

  90[a](#tfn7-copd-12-141){ref-type="table-fn"} (39--141)                                                                                                                                                                                                                                   

  90[a](#tfn7-copd-12-141){ref-type="table-fn"} (39--142)                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                            

  Decramer et al[@b23-copd-12-141] (study 2)                                                                24 weeks   UMEC--VI 125/25 µg OD[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                 Change from baseline:                                              Mean 0- to 6-hour FEV~1~ on day 168 for both doses of UMEC/VI improved vs tiotropium 18 µg (nominal *P*-values)
                                                                                                                       UMEC--VI 62.5/25 µg OD vs Tiotropium 18 µg OD\                                                                                                                       
                                                                                                                       Umeclidinium 125 µg OD                                                                                                                                               

                                                                                                                                                                                                                                                                                            

  60[a](#tfn7-copd-12-141){ref-type="table-fn"} (10--109)                                                                                                                                                                                                                                   

  22 (-27 to 72)                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                            

  Maleki-Yazdi et al[@b32-copd-12-141]                                                                      24 weeks   UMEC--VI 62.5/25 µg OD vs tiotropium 18 µg OD                                                     Change from baseline:                                              Weighted mean FEV~1~ over 0--6 hours postdose at day 168 improved for UMEC--VI vs tiotropium (105 mL, 95% CI 0.071--0.14; *P*\<0.001)

  112[a](#tfn7-copd-12-141){ref-type="table-fn"} (81--144)                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                            

  Maltais et al[@b33-copd-12-141] (study 417)                                                               12 weeks   UMEC--VI 125/25 µg OD[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                 Change from baseline vs placebo:                                   Trough FEV~1~ numerically improved with UMEC--VI 125/25 µg and UMEC--VI 62.5/25 µg compared with placebo from day 2 to week 12
                                                                                                                       UMEC--VI 62.5/25 µg OD\                                                                                                                                              
                                                                                                                       Umeclidinium 62.5 µg OD\                                                                                                                                             
                                                                                                                       Umeclidinium 125 µg OD\                                                                                                                                              
                                                                                                                       Vilanterol 25 µg OD                                                                                                                                                  

  211[a](#tfn7-copd-12-141){ref-type="table-fn"} (172--249)                                                                                                                                                                                                                                 

  87[a](#tfn7-copd-12-141){ref-type="table-fn"} (30--143)                                                                                                                                                                                                                                   

  140[a](#tfn7-copd-12-141){ref-type="table-fn"} (84--96)                                                                                                                                                                                                                                   

  99[a](#tfn7-copd-12-141){ref-type="table-fn"} (50--148)                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                            

  Maltais et al[@b33-copd-12-141] (study 418)                                                               12 weeks   UMEC--VI 125/25 µg OD[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                 Change from baseline vs placebo:                                   Trough FEV~1~ improved with UMEC--VI 125/25 µg and UMEC--VI 62.5/25 µg compared with placebo (*P*\<0.001) from day 2 to week 12
                                                                                                                       UMEC--VI 62.5/25 µg OD\                                                                                                                                              
                                                                                                                       Umeclidinium 62.5 µg OD\                                                                                                                                             
                                                                                                                       Umeclidinium 125 µg OD\                                                                                                                                              
                                                                                                                       Vilanterol 25 µg OD                                                                                                                                                  

  243[a](#tfn7-copd-12-141){ref-type="table-fn"} (202--284)                                                                                                                                                                                                                                 

  144[a](#tfn7-copd-12-141){ref-type="table-fn"} (86--203)                                                                                                                                                                                                                                  

  255[a](#tfn7-copd-12-141){ref-type="table-fn"} (193--318)                                                                                                                                                                                                                                 

  112[a](#tfn7-copd-12-141){ref-type="table-fn"} (61--163)                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                            

  Donohue et al[@b27-copd-12-141] (study 2114930)                                                           12 weeks   UMEC--VI 62.5/25 µg OD vs SFC 50/250 µg BID                                                       Change from baseline:                                              FEV~1~ significantly improved for UMEC--VI vs SFC at all time points on day 84 (except 18 hours); significantly greater improvement in LSM trough FEV~1~ from baseline for UMEC--VI vs SFC on day 85 (treatment difference 82 mL, *P*\<0.001)

  74[a](#tfn7-copd-12-141){ref-type="table-fn"} (38--110)                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                            

  Donohue et al[@b27-copd-12-141] (study 2114951)                                                           12 weeks   UMEC--VI 62.5/25 µg OD vs SFC 50/250 µg BID                                                       Change from baseline:                                              FEV~1~ significantly improved for UMEC--VI vs SFC at all time points on day 84; significantly greater improvement in LSM trough FEV~1~ from baseline for UMEC--VI vs SFC on day 85 (treatment difference 98 mL, *P*\<0.001)

  101[a](#tfn7-copd-12-141){ref-type="table-fn"} (63--139)                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                            

  **TIO--OLO**                                                                                                                                                                                                                                                                              

  Buhl et al[@b30-copd-12-141] (study 1237.5)                                                               52 weeks   TIO--OLO 2.5/5 µg OD[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                  Change from baseline                                               Improvements observed for FEV~1~ values on all test days over each of the 52-week studies; responses in trough FVC and FVC AUC~0--3\ h~ over 24 weeks consistent with the primary end points
                                                                                                                       TIO--OLO 5/5 µg OD vs Olodaterol 5 µg OD\                                                                                                                            
                                                                                                                       Tiotropium 5 µg OD\                                                                                                                                                  
                                                                                                                       Tiotropium 2.5 µg OD                                                                                                                                                 

  at week 24:                                                                                                                                                                                                                                                                               

  82[a](#tfn7-copd-12-141){ref-type="table-fn"} (59--106)                                                                                                                                                                                                                                   

  71[a](#tfn7-copd-12-141){ref-type="table-fn"} (47--94)                                                                                                                                                                                                                                    

  NR                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                            

  Buhl et al[@b30-copd-12-141] (study 1237.6)                                                               52 weeks   TIO--OLO 2.5/5 µg OD[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                  Change from baseline                                               Improvements observed for FEV~1~ values on all test days over each of the 52-week studies; responses in trough FVC and FVC AUC~0--3\ h~ over 24 weeks consistent with the primary end points
                                                                                                                       TIO--OLO 5/5 µg OD vs Olodaterol 5 µg OD\                                                                                                                            
                                                                                                                       Tiotropium 5 µg OD\                                                                                                                                                  
                                                                                                                       Tiotropium 2.5 µg OD                                                                                                                                                 

  at week 24:                                                                                                                                                                                                                                                                               

  88[a](#tfn7-copd-12-141){ref-type="table-fn"} (63--113)                                                                                                                                                                                                                                   

  50[a](#tfn7-copd-12-141){ref-type="table-fn"} (24--75)                                                                                                                                                                                                                                    

  NR                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                            

  Beeh et al[@b31-copd-12-141] (VIVACITO)                                                                   6 weeks    TIO--OLO 2.5/5 µg OD[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                  Adjusted mean difference:                                          Significant improvement in FEV~1~ AUC~0--24\ h~ and greater improvement in 24-hour FEV~1~ profile for both TIO--OLO doses vs placebo and monotherapies at 6 weeks; similar pattern of response for FVC, FRC, and residual volume
                                                                                                                       TIO--OLO 5/5 µg OD vs Olodaterol 5 µg OD\                                                                                                                            
                                                                                                                       Tiotropium 5 µg OD\                                                                                                                                                  
                                                                                                                       Tiotropium 2.5 µg OD\                                                                                                                                                
                                                                                                                       Placebo                                                                                                                                                              

  92[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                        

  79[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                        

  NR                                                                                                                                                                                                                                                                                        

  207[a](#tfn7-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                            

  **ACL--FORM**                                                                                                                                                                                                                                                                             

  Singh et al[@b28-copd-12-141] (ACLIFORM-COPD)                                                             24 weeks   ACL--FORM 400/6 µg BID[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                Change from baseline at week 24:                                   Fast onset of action of both ACL--FORM doses on day 1, with significant improvements in bronchodilation vs placebo at 5 minutes postdose
                                                                                                                       ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                                                                                                     
                                                                                                                       Aclidinium 400 µg BID\                                                                                                                                               
                                                                                                                       Placebo                                                                                                                                                              

  85[a](#tfn7-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                             

  \~25[d](#tfn10-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                          

  143[a](#tfn7-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                            

  D'Urzo et al[@b29-copd-12-141] (AUGMENT)                                                                  24 weeks   ACL--FORM 400/6 µg BID[c](#tfn9-copd-12-141){ref-type="table-fn"}\                                Change from baseline at week 24:                                   ACL--FORM (both doses) associated with significant changes from baseline in peak FEV~1~ at day 1 and week 24 (*P*\<0.0001 all comparisons); rapid bronchodilation occurred with significant FEV~1~ improvements 5 minutes postdose (*P*\<0.0001)
                                                                                                                       ACL--FORM 400/12 µg\                                                                                                                                                 
                                                                                                                       BID vs Formoterol 12 µg BID\                                                                                                                                         
                                                                                                                       Aclidinium 400 µg BID\                                                                                                                                               
                                                                                                                       Placebo                                                                                                                                                              

  45[a](#tfn7-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                             

  28                                                                                                                                                                                                                                                                                        

  129[a](#tfn7-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Treatment once daily unless stated otherwise.

Significant treatment difference;

FEV1 AUC~0--4\ h~;

dose not approved for use (ACL--FORM, dose not approved in EU);

estimated from figure.

**Abbreviations:** ACL--FORM, aclidinium--formoterol; AUC~0--3\ h~, area under the plasma concentration-time curve from 0 to 3 hours; AUC~0--4\ h~, area under the (plasma concentration--time) curve from 0 to 4 hours; AUC~0--12\ h~, area under the (plasma concentration--time) curve from 0 to 12 hours; AUC~0--24\ h~, area under the (plasma concentration--time) curve from 0 to 24 hours; BID, bis in die (twice daily); CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; FRC, functional residual capacity; IC, inspiratory capacity; IND--GLY, indacaterol--glycopyrronium; LSM, least-squares mean; NR, not reported; NS, not significant; OD, once daily; OL, open-label; SFC, salmeterol/fluticasone combination; TIO--OLO, tiotropium--olodaterol; UMEC--VI, umeclidinium--vilanterol.

###### 

Symptoms: margin of efficacy of fixed combinations versus comparators in published studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference and study                                                  Duration                                                            Treatment                                                                                                                                                                                                                                                                                                                                                                   Treatment difference at end point                                                                                  
  -------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **IND--GLY**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Bateman et al[@b2-copd-12-141] (SHINE)                               26 weeks                                                            IND--GLY 110/50 µg OD vs Indacaterol 150 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                Diary data (values vs placebo): % days with no daytime symptoms, +3.05[b](#tfn14-copd-12-141){ref-type="table-fn"}; % days able to perform usual daily activities, +11.48[b](#tfn14-copd-12-141){ref-type="table-fn"}--[e](#tfn17-copd-12-141){ref-type="table-fn"}; % nights without awakenings, +10.01[b](#tfn14-copd-12-141){ref-type="table-fn"},[c](#tfn15-copd-12-141){ref-type="table-fn"}
                                                                                                                                           Glycopyrronium 50 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                           Tiotropium 18 µg OD OL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  0.25 (NR)                                                            3.5 (NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  0.20 (NR)                                                            4.4 (NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  0.51[b](#tfn14-copd-12-141){ref-type="table-fn"} (NR)                8.9[b](#tfn14-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  1.09[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.61--1.57)        10.6[b](#tfn14-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Dahl et al[@b36-copd-12-141] (ENLIGHTEN)                             52 weeks                                                            IND--GLY 110/50 µg OD vs Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                               Diary data:

  NR                                                                   NR                                                                  Total daily symptom score, −0.573[b](#tfn14-copd-12-141){ref-type="table-fn"}; % days with no daytime symptoms, +5.3[b](#tfn14-copd-12-141){ref-type="table-fn"}, % days able to perform usual daily activities, +8.1[b](#tfn14-copd-12-141){ref-type="table-fn"}; % nights without awakenings, +6.3                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Dahl et al[@b37-copd-12-141] (BEACON)                                4 weeks                                                             IND--GLY 110/50 µg OD vs indacaterol 150 µg OD + glycopyrronium 50 µg OD                                                                                                                                                                                                                                                                                                                                                                                                                       Diary data:

  NR                                                                   NR                                                                  Total daily symptom score, 0.07 (−0.24, 0.39)                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Mahler et al[@b38-copd-12-141] (BLAZE)                               6 weeks                                                             IND--GLY 110/50 µg OD vs tiotropium 18 µg OD\                                                                                                                                                                                                                                                                                                                               SAC TDI:                                                                                                SAC TDI:   Diary data (vs placebo and tiotropium):
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  0.49[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.07, 0.91)        11.5[b](#tfn14-copd-12-141){ref-type="table-fn"} (2.78)             Total daily symptom score, −0.72[b](#tfn14-copd-12-141){ref-type="table-fn"} and −0.03; % days with no daytime symptoms, +3.5[b](#tfn14-copd-12-141){ref-type="table-fn"} and +1.5; % nights with no awakenings, 5.6[b](#tfn14-copd-12-141){ref-type="table-fn"} and 2.6; days able to perform usual activities, 8.8[b](#tfn14-copd-12-141){ref-type="table-fn"} and −0.4                                                                                                                      

  1.37[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.95, 1.79)        17.8[b](#tfn14-copd-12-141){ref-type="table-fn"} (1.78)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Vogelmeier et al[@b39-copd-12-141] (ILLUMINATE)                      26 weeks                                                            IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                     Diary data:

  0.76[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.26, 1.26)        10.7[b](#tfn14-copd-12-141){ref-type="table-fn"} (1.56)             Differences in scores for most symptoms NS between treatment groups\                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                           % days with no daytime symptoms, +2.50[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Beeh et al[@b35-copd-12-141] (BRIGHT)                                3 weeks                                                             IND--GLY 110/50 µg OD vs tiotropium 18 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                  Diary data, mean daily symptom score vs baseline:\
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        IND--GLY −0.64, tiotropium −0.43, placebo −0.19

  NR                                                                   NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  NR                                                                   NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Buhl et al[@b25-copd-12-141] (QUANTIFY)                              26 weeks                                                            IND--GLY 110/50 µg OD vs tiotropium 18 µg OD + formoterol 12 µg BID                                                                                                                                                                                                                                                                                                                                                                                                                            LSM treatment difference in SGRQ-C symptom score IND--GLY vs tiotropium + formoterol (−1.31 \[95% CI −3.49, 0.86\])

  0.38 (−0.06, 0.82)                                                   7.2 (1.17 risk ratio)[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Zhong et al[@b24-copd-12-141] (LANTERN)                              26 weeks                                                            IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                     Improvements in TDI focal score at weeks 12 and 26 similar between IND--GLY and SFC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Similar improvement in SGRQ total score between IND--GLY and SFC at weeks 12 and 26\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Symptoms, rescue medication use and total COPD assessment test scores at week 26 comparable for IND--GLY and SFC

  0.25 (−0.09, 0.59)                                                   NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **UMEC--VI**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Donohue et al[@b41-copd-12-141]                                      24 weeks                                                            UMEC--VI 62.5/25 µg OD vs umeclidinium 62.5 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                             NR
                                                                                                                                           Vilanterol 25 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  0.3 (−0.2, 0.7)                                                      5.0 (NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  0.4 (−1.0, 0.8)                                                      7.0[b](#tfn14-copd-12-141){ref-type="table-fn"} (1.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  1.2[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.7, 1.7)           17.0[b](#tfn14-copd-12-141){ref-type="table-fn"} (2.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Decramer et al[@b23-copd-12-141] (study 1)                           24 weeks                                                            UMEC--VI 125/25 µg OD[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                           UMEC--VI 62.5/25 µg OD vs tiotropium 18 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                           Vilanterol 25 µg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  −0.1 (−0.7, 0.5)                                                     5 (0.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  0.2 (−0.4, 0.8)                                                      6 (1.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Decramer et al[@b23-copd-12-141] (study 2)                           24 weeks                                                            UMEC--VI 125/25 µg OD[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                           UMEC--VI 62.5/25 µg OD vs tiotropium 18 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                           Umeclidinium 125 µg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  0.2 (−0.5, 0.9)                                                      6 (1.3)                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  0.4 (−0.3, 1.1)                                                      7 (1.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Donohue et al[@b27-copd-12-141] (study 2114930)                      12 weeks                                                            UMEC--VI 62.5/25 µg OD vs SFC 50/250 µg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  0.3 (−0.2, 0.7)                                                      NR                                                                  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Donohue et al[@b27-copd-12-141] (study 2114951)                      12 weeks                                                            UMEC--VI 62.5/25 µg OD vs SFC 50/250 µg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  0.3 (−0.1, 0.8)                                                      NR                                                                  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Maltais et al[@b33-copd-12-141] (study 417)                          12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Exercise dyspnea scale (Borg), changes from baseline vs placebo:

  UMEC--VI 125/25 µg OD[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                                   −0.25 (−0.57 to 0.07)[f](#tfn18-copd-12-141){ref-type="table-fn"}                                                  
  UMEC--VI 62.5/25 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Umeclidinium 62.5 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Umeclidinium 125 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Vilanterol 25 µg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  −0.05 (−0.37 to 0.27)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                   NR                                                                  −0.16 (−0.61 to 0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  NR                                                                   NR                                                                  −0.13 (−0.58 to 0.33)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  NR                                                                   NR                                                                  0.39 (−0.01 to 0.79)                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Maltais et al[@b33-copd-12-141] (study 418)                          12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Exercise dyspnea scale (Borg), change from baseline vs placebo:

  UMEC--VI 125/25 µg OD[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                                   −0.34 (−0.76 to 0.03)[f](#tfn18-copd-12-141){ref-type="table-fn"}                                                  
  UMEC--VI 62.5/25 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Umeclidinium 62.5 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Umeclidinium 125 µg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Vilanterol 25 µg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  −0.36 (0.67 to −0.05)[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  NR                                                                   NR                                                                  −0.32 (−0.78 to 0.13)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  NR                                                                   NR                                                                  −0.66 (−1.14 to −0.18)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  NR                                                                   NR                                                                  −0.36 (−0.76 to 0.03)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **TIO--OLO**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Buhl et al[@b30-copd-12-141] (studies 1237.5 and 1237.6 combined)    52 weeks                                                            TIO--OLO 2.5/5 µg OD[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                           (At week 24):                                                                                                      
                                                                                                                                           TIO--OLO 5/5 µg OD vs Olodaterol 5 µg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  0.420[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.155--0.684)     NR                                                                  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Tiotropium 5 µg OD                                                   0.356[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.092--0.619)    NR                                                                                                                                                                                                                                                                                                                                                                          NR                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **ACL--FORM**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Singh et al[@b28-copd-12-141] (ACLIFORM-COPD)                        24 weeks                                                            ACL--FORM 400/6 µg BID[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                            E-RS changes from baseline:
                                                                                                                                           ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                           Aclidinium 400 µg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  0.45 (0--0.9)                                                        3.5 (1.19)                                                          −0.69 (−6.2)[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                       

  0.40 (−0.05 to 0.85)                                                 8.3 (1.42)                                                          −0.89 (−8.4)[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Placebo                                                              1.29[b](#tfn14-copd-12-141){ref-type="table-fn"} (0.73--1.86)       19.3 (2.54)[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                     −0.82 (−8.2)[b](#tfn14-copd-12-141){ref-type="table-fn"},[g](#tfn19-copd-12-141){ref-type="table-fn"}              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                           ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                               Nighttime symptoms, change from baseline:
                                                                                                                                           Aclidinium 400 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  NR                                                                   NR                                                                  −0.04 (−4.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                   NR                                                                  −0.09[b](#tfn14-copd-12-141){ref-type="table-fn"} (−10.5)                                                                                                                                                                                                                                                                                                                                                                                                                                      

  NR                                                                   NR                                                                  −0.07 (−8)[g](#tfn19-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                           ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                               Early morning symptoms, change from baseline vs:
                                                                                                                                           ACL 400 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  NR                                                                   NR                                                                  −0.04 (−3.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                   NR                                                                  −0.08 (−7.5)[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                       

  NR                                                                   NR                                                                  −0.09 (−8.1)[b](#tfn14-copd-12-141){ref-type="table-fn"},[g](#tfn19-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  D'Urzo et al[@b29-copd-12-141] (AUGMENT)                             24 weeks                                                            ACL--FORM 400/6 µg BID[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                            E-RS changes from baseline:
                                                                                                                                           ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                           Aclidinium 400 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  0.5                                                                  6.4                                                                 −0.48 (−3.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  0.46                                                                 3.3                                                                 −0.32 (−1.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  1.44[b](#tfn14-copd-12-141){ref-type="table-fn"}                     21.5 (2.8)[b](#tfn14-copd-12-141){ref-type="table-fn"}              −1.36 (−10.8)[b](#tfn14-copd-12-141){ref-type="table-fn"},[g](#tfn19-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                           ACL--FORM 400/6 µg BID[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                            Night-time symptoms, change from baseline vs:
                                                                                                                                           ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                           Aclidinium 400 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  NR                                                                   NR                                                                  −0.05 (−2.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                   NR                                                                  −0.08 (−5.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                   NR                                                                  −0.12 (−9.3)[b](#tfn14-copd-12-141){ref-type="table-fn"},[g](#tfn19-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                           ACL--FORM 400/6 µg BID[f](#tfn18-copd-12-141){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                            Early-morning symptoms, change from baseline vs:
                                                                                                                                           ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                           Aclidinium 400 µg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  NR                                                                   NR                                                                  −0.06 (−4.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                   NR                                                                  −0.09 (−7.4)[b](#tfn14-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                       

  NR                                                                   NR                                                                  −0.13 (−9.8)[b](#tfn14-copd-12-141){ref-type="table-fn"},[g](#tfn19-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Treatment once daily unless stated otherwise.

TDI responders had improvement ≥1 unit in TDI score.

Significant treatment difference. Significant treatment difference versus

indacaterol,

glycopyrronium or

tiotropium (values NR).

Dose not approved for use (ACL--FORM, dose not approved in EU).

Values in parentheses are differences expressed in percentage points (not percentage differences).

**Abbreviations:** ACL--FORM, aclidinium--formoterol; BID, bis in die (twice daily); CI, confidence interval; E-RS, Evaluating Respiratory Symptoms; IND--GLY, indacaterol--glycopyrronium; LSM, least-squares mean; NR, not reported; NS, not significant; OR, odds ratio; SAC, self-administered, computerized; SFC, salmeterol--fluticasone combination; SGRQ-C, St George's Respiratory Questionnaire -- COPD; TIO--OLO, tiotropium--olodaterol; TDI, transition dyspnea index; UMEC--VI, umeclidinium--vilanterol.

###### 

Rescue-medication use: margin of efficacy of fixed combinations versus comparators in published studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference and study                                                  Duration   Treatment                                                                                   Rescue albuterol/salbutamol puffs/day change from baseline, LSM (95% CI) treatment difference at end point
  -------------------------------------------------------------------- ---------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  **IND--GLY**                                                                                                                                                                

  Bateman et al[@b2-copd-12-141] (SHINE)                               26 weeks   IND--GLY 110/50 µg OD vs Indacaterol 150 µg OD\                                             
                                                                                  Glycopyrronium 50 µg OD\                                                                    
                                                                                  Tiotropium 18 µg OD OL\                                                                     
                                                                                  Placebo                                                                                     

  −0.31[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

  −0.66[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

  −0.55[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

  −0.96[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.29 to −0.62)                                                                                                          

                                                                                                                                                                              

  Dahl et al[@b36-copd-12-141] (ENLIGHTEN)                             52 weeks   IND--GLY 110/50 µg OD vs Placebo                                                            

  −0.73[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

                                                                                                                                                                              

  Dahl et al[@b37-copd-12-141] (BEACON)                                4 weeks    IND--GLY 110/50 µg OD vs Indacaterol 150 µg OD + glycopyrronium 50 µg OD                    

  −0.04 (−0.35 to 0.28)                                                                                                                                                       

                                                                                                                                                                              

                                                                                                                                                                              

  Mahler et al[@b38-copd-12-141] (BLAZE)                               6 weeks    IND--GLY 110/50 µg OD vs Placebo\                                                           
                                                                                  Tiotropium 18 µg OD                                                                         

  −1.43[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.72 to −1.13)                                                                                                          

  −0.45[a](#tfn22-copd-12-141){ref-type="table-fn"} (−0.74 to −0.16)                                                                                                          

                                                                                                                                                                              

  Vogelmeier et al[@b39-copd-12-141] (ILLUMINATE)                      26 weeks   IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                  

  −0.39[a](#tfn22-copd-12-141){ref-type="table-fn"} (−0.71 to −0.06)                                                                                                          

                                                                                                                                                                              

  Wedzicha et al[@b40-copd-12-141] (SPARK)                             64 weeks   IND--GLY 110/50 µg OD vs Glycopyrronium 50 µg OD\                                           
                                                                                  Tiotropium 18 µg OD OL                                                                      

  −0.81[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

  −0.76[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

                                                                                                                                                                              

  Beeh et al[@b35-copd-12-141] (BRIGHT)                                3 weeks    IND--GLY 110/50 µg OD vs Tiotropium 18 µg[a](#tfn22-copd-12-141){ref-type="table-fn"} OD\   
                                                                                  Placebo                                                                                     

  −1.08[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

  −1.23[a](#tfn22-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                      

                                                                                                                                                                              

  Zhong et al[@b24-copd-12-141] (LANTERN)                              26 weeks   IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                  

  −0.03 (−0.26 to 0.21)                                                                                                                                                       

                                                                                                                                                                              

  Wedzicha et al[@b26-copd-12-141] (FLAME)                             52 weeks   IND--GLY 110/50 µg OD vs SFC 50/500 µg BID                                                  

  −0.25[a](#tfn22-copd-12-141){ref-type="table-fn"} (−0.38 to −0.12)                                                                                                          

                                                                                                                                                                              

  **UMEC--VI**                                                                                                                                                                

  Donohue et al[@b41-copd-12-141]                                      24 weeks   UMEC--VI 62.5/25 µg OD vs Umeclidinium 62.5 µg OD\                                          
                                                                                  Vilanterol 25 µg OD\                                                                        
                                                                                  Placebo                                                                                     

  −0.6[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.0 to −0.1)                                                                                                             

  0.1 (−0.3 to 0.5)                                                                                                                                                           

  −0.8[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.3 to −0.3)                                                                                                             

                                                                                                                                                                              

  Decramer et al[@b23-copd-12-141] (study 1)                           24 weeks   UMEC--VI 125/25 µg OD[b](#tfn23-copd-12-141){ref-type="table-fn"}\                          
                                                                                  UMEC--VI 62.5/25 µg OD vs Tiotropium 18 µg OD\                                              
                                                                                  Vilanterol 25 µg OD                                                                         

                                                                                                                                                                              

  −0.7[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.2 to −0.1)                                                                                                             

  −0.3 (−0.8 to 0.3)                                                                                                                                                          

                                                                                                                                                                              

  Decramer et al[@b23-copd-12-141] (study 2)                           24 weeks   UMEC--VI 125/25 µg OD[b](#tfn23-copd-12-141){ref-type="table-fn"}\                          
                                                                                  UMEC--VI 62.5/25 µg OD vs Tiotropium 18 µg OD\                                              
                                                                                  Umeclidinium 125 µg OD                                                                      

                                                                                                                                                                              

  −0.6 (−1.2 to 0)                                                                                                                                                            

  −0.6 (−1.2 to 0)                                                                                                                                                            

                                                                                                                                                                              

  Maleki-Yazdi et al[@b32-copd-12-141]                                 24 weeks   UMEC--VI 62.5/25 µg OD vs Tiotropium 18 µg OD                                               

  −0.5[a](#tfn22-copd-12-141){ref-type="table-fn"} (−0.7 to −0.2)                                                                                                             

                                                                                                                                                                              

  Maltais et al[@b33-copd-12-141] (study 417)                          12 weeks   UMEC--VI 125/25 µg OD[b](#tfn23-copd-12-141){ref-type="table-fn"}\                          Differences from placebo:
                                                                                  UMEC--VI 62.5/25 µg OD\                                                                     
                                                                                  Umeclidinium 62.5 µg OD\                                                                    
                                                                                  Umeclidinium 125 µg OD\                                                                     
                                                                                  Vilanterol 25 µg OD                                                                         

  −0.6[a](#tfn22-copd-12-141){ref-type="table-fn"} (−0.8 to −0.3)                                                                                                             

  −0.2 (−0.6 to 0.1)                                                                                                                                                          

  −0.6[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1 to −0.2)                                                                                                               

  −0.4[a](#tfn22-copd-12-141){ref-type="table-fn"} (−0.7 to 0)                                                                                                                

                                                                                                                                                                              

  Maltais et al[@b33-copd-12-141] (study 418)                          12 weeks   UMEC--VI 125/25 µg OD[b](#tfn23-copd-12-141){ref-type="table-fn"}\                          Differences from placebo:
                                                                                  UMEC--VI 62.5/25 µg OD\                                                                     
                                                                                  Umeclidinium 62.5 µg OD\                                                                    
                                                                                  Umeclidinium 125 µg OD\                                                                     
                                                                                  Vilanterol 25 µg OD                                                                         

  −1.2[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.5 to −0.8)                                                                                                             

  −0.7[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.3 to −0.2)                                                                                                             

  −1.0[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.5 to −0.4)                                                                                                             

  −0.8[a](#tfn22-copd-12-141){ref-type="table-fn"} (−1.2 to −0.3)                                                                                                             

                                                                                                                                                                              

  Donohue et al[@b27-copd-12-141] (study 2114930)                      12 weeks   UMEC--VI 62.5/25 µg OD vs SFC 50/250 µg BID                                                 

  0 (−0.3 to 0.2)                                                                                                                                                             

                                                                                                                                                                              

  Donohue et al[@b27-copd-12-141] (study 2114951)                      12 weeks   UMEC--VI 62.5/25 µg OD vs SFC 50/250 µg BID                                                 

  −0.3[a](#tfn22-copd-12-141){ref-type="table-fn"} (−0.6 to −0.1)                                                                                                             

                                                                                                                                                                              

  **TIO--OLO**                                                                                                                                                                

  Buhl et al[@b30-copd-12-141] (studies 1237.5 and 1237.6 combined)    52 weeks   TIO--OLO 2.5/5 µg OD[b](#tfn23-copd-12-141){ref-type="table-fn"}\                           
                                                                                  TIO--OLO 5/5 µg OD vs Olodaterol 5 µg OD\                                                   
                                                                                  Tiotropium 5 µg OD                                                                          

                                                                                                                                                                              

  \~ −0.4[c](#tfn24-copd-12-141){ref-type="table-fn"}                                                                                                                         

  \~ −0.8[c](#tfn24-copd-12-141){ref-type="table-fn"}                                                                                                                         

                                                                                                                                                                              

  **ACL--FORM**                                                                                                                                                               

  Singh et al[@b28-copd-12-141] (ACLIFORM-COPD)                        24 weeks   ACL--FORM 400/6 µg BID[b](#tfn23-copd-12-141){ref-type="table-fn"}\                         
                                                                                  ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                            
                                                                                  Aclidinium 400 µg BID\                                                                      
                                                                                  Placebo                                                                                     

                                                                                                                                                                              

                                                                                                                                                                              

  NS                                                                                                                                                                          

  Value NR[a](#tfn22-copd-12-141){ref-type="table-fn"}                                                                                                                        

  −0.66[a](#tfn22-copd-12-141){ref-type="table-fn"}                                                                                                                           

                                                                                                                                                                              

  D'Urzo et al[@b29-copd-12-141] (AUGMENT)                             24 weeks   ACL--FORM 400/6 µg BID[b](#tfn23-copd-12-141){ref-type="table-fn"}\                         
                                                                                  ACL--FORM 400/12 µg BID vs Formoterol 12 µg BID\                                            
                                                                                  Aclidinium 400 µg BID\                                                                      
                                                                                  Placebo                                                                                     

                                                                                                                                                                              

                                                                                                                                                                              

  0.21                                                                                                                                                                        

  0.43[a](#tfn22-copd-12-141){ref-type="table-fn"}                                                                                                                            

  Value NR[a](#tfn22-copd-12-141){ref-type="table-fn"}                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Treatment once daily unless stated otherwise.

Significant treatment difference;

dose not approved for use;

estimated from figure. Statistical analysis not reported.

**Abbreviations:** ACL--FORM, aclidinium--formoterol; BID, bis in die (twice daily); CI, confidence interval; IND--GLY, indacaterol--glycopyrronium; LSM, least-squares mean; NR, not reported; NS, not significant; OL, open-label; SFC, salmeterol--fluticasone combination; TIO--OLO, tiotropium--olodaterol; UMEC--VI, umeclidinium--vilanterol.

###### 

Exacerbations: margin of efficacy of fixed combinations versus comparators in published studies that included exacerbations as an efficacy outcome

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference and study                                                                                          Duration                                                                                                     Treatment                                                             Exacerbation definition                                                                                                                                                                                                                                                                                                                                                                                                                       Treatment difference at end point   
  ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  **IND--GLY**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Wedzicha et al[@b40-copd-12-141] (SPARK)                                                                     64 weeks                                                                                                     IND--GLY 110/50 μg OD vs Glycopyrronium 50 μg OD\                     Presence of two major symptoms (dyspnea, sputum volume, sputum purulence) for ≥2 consecutive days or worsening of one major symptom plus increase in one minor symptom (sore throat, colds, fever without other cause, cough, wheeze) for ≥2 consecutive days                                                                                                                                                                                                                     
                                                                                                                                                                                                                            Tiotropium 18 μg OD OL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  0.85[a](#tfn27-copd-12-141){ref-type="table-fn"},[b](#tfn28-copd-12-141){ref-type="table-fn"} (0.77--0.94)   0.79[c](#tfn29-copd-12-141){ref-type="table-fn"} (0.60--1.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  0.86[a](#tfn27-copd-12-141){ref-type="table-fn"},[b](#tfn28-copd-12-141){ref-type="table-fn"} (0.78--0.94)   1.13[c](#tfn29-copd-12-141){ref-type="table-fn"} (0.83--1.53)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Buhl et al[@b25-copd-12-141] (QUANTIFY)                                                                      26 weeks                                                                                                     IND--GLY 110/50 μg OD vs tiotropium 18 μg OD + formoterol 12 μg BID   Moderate exacerbations were those managed with antibiotics and/or systemic corticosteroids; severe exacerbations were those that resulted in hospitalization                                                                                                                                                                                                                                                                                                                      

  0.85 (0.62--1.17)                                                                                            NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Zhong et al[@b24-copd-12-141] (LANTERN)                                                                      26 weeks                                                                                                     IND--GLY 110/50 μg OD vs SFC 50/500 μg BID                            An exacerbation was considered moderate if patients were treated with systemic corticosteroids, antibiotics, or both. Exacerbations were considered severe if patients were hospitalized or experienced an emergency room visit ≥24 hours                                                                                                                                                                                                                                         

  0.69[a](#tfn27-copd-12-141){ref-type="table-fn"} (0.48--1)                                                   0.32 (0.12--0.88)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Wedzicha et al[@b26-copd-12-141] (FLAME)                                                                     52 weeks                                                                                                     IND--GLY 110/50 μg OD vs SFC 50/500 μg BID                            COPD exacerbations were categorized as mild (involving worsening of symptoms for \>2 consecutive days, but not leading to treatment with systemic glucocorticoids or antibiotics), moderate (leading to treatment with systemic glucocorticoids, antibiotics, or both), or severe (leading to hospital admission or a visit to the ER that lasted \>24 hours, in addition to treatment with systemic glucocorticoids, antibiotics, or both)                                       

  0.89[a](#tfn27-copd-12-141){ref-type="table-fn"},[b](#tfn28-copd-12-141){ref-type="table-fn"} (0.83--0.96)   0.84[a](#tfn27-copd-12-141){ref-type="table-fn"},[b](#tfn28-copd-12-141){ref-type="table-fn"} (0.78--0.91)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **UMEC--VI**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Donohue et al[@b41-copd-12-141]                                                                              24 weeks                                                                                                     UMEC--VI 62.5/25 μg OD vs Umeclidinium 62.5 μg OD\                    Acute worsening of COPD symptoms requiring emergency treatment, hospitalization, or use of additional pharmacotherapy beyond study drug or rescue salbutamol (eg, oral steroids and antibiotics)                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                            Vilanterol 25 μg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                            Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  NR                                                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR                                                                                                           0.5[a](#tfn27-copd-12-141){ref-type="table-fn"} (0.3--0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Decramer et al[@b23-copd-12-141] (study 1)                                                                   24 weeks                                                                                                     UMEC--VI 125/25 μg OD[d](#tfn30-copd-12-141){ref-type="table-fn"}\    Acute worsening of COPD symptoms requiring use of any treatment other than study drug or rescue salbutamol                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                            UMEC--VI 62.5/25 μg OD vs Tiotropium 18 μg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                            Vilanterol 25 μg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  NR                                                                                                           1.2 (0.5--2.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  NR                                                                                                           0.7 (0.4--1.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Decramer et al[@b23-copd-12-141] (study 2)                                                                   24 weeks                                                                                                     UMEC--VI 125/25 μg OD[d](#tfn30-copd-12-141){ref-type="table-fn"}\    Acute worsening of COPD symptoms requiring use of any treatment other than study drug or rescue salbutamol                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                            UMEC--VI 62.5/25 μg OD vs Tiotropium 18 μg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                            Umeclidinium 125 μg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  NR                                                                                                           1.9 (1--3.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  NR                                                                                                           1 (0.6--1.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Maleki-Yazdi et al[@b32-copd-12-141]                                                                         24 weeks                                                                                                     UMEC--VI 62.5/25 μg OD vs tiotropium 18 μg OD                         Acute worsening of COPD symptoms requiring use of any treatment other than study drug or rescue albuterol/salbutamol                                                                                                                                                                                                                                                                                                                                                              

  NR                                                                                                           0.5[a](#tfn27-copd-12-141){ref-type="table-fn"} (0.3--1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **TIO--OLO**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Buhl et al[@b30-copd-12-141] (studies 1237.5 and 1237.6 combined)                                            52 weeks                                                                                                     TIO--OLO 2.5/5 μg OD[d](#tfn30-copd-12-141){ref-type="table-fn"}\     "Moderate/severe" (not defined)                                                                                                                                                                                                                                                                                                                                                                                                                                                   Kaplan--Meier plot shows descending probability in the following order: olodaterol 5 μg; tiotropium 2.5 μg; tiotropium 5 μg;\
                                                                                                                                                                                                                            TIO--OLO 5/5 μg OD vs Olodaterol 5 μg OD\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               TIO--OLO 5/5 μg;\
                                                                                                                                                                                                                            Tiotropium 5 μg OD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      TIO--OLO 2.5/5 μg (statistical analysis NR)

  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **ACL--FORM**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Singh et al[@b28-copd-12-141] (ACLIFORM-COPD)                                                                24 weeks                                                                                                     ACL--FORM 400/6 μg BID[d](#tfn30-copd-12-141){ref-type="table-fn"}\   HCRU: an increase of COPD symptoms during ≥2 consecutive days that requires a change in COPD treatment                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                            ACL--FORM 400/12 μg BID vs Formoterol 12 μg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                            Aclidinium 400 μg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                            Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  0.64 (0.4--1)                                                                                                NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  0.89 (0.6--1.4)                                                                                              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  0.73 (0.4--1.2)                                                                                              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                            ACL--FORM 400/6 μg BID[d](#tfn30-copd-12-141){ref-type="table-fn"}\   EXACT: an increase from baseline in total EXACT score ≥9 points for ≥3 days or ≥12 points for ≥2 days[e](#tfn31-copd-12-141){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                            ACL--FORM 400/12 μg BID vs Formoterol 12 μg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                            Aclidinium 400 μg BID\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                            Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  0.86 (0.7--1.1)                                                                                              NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  0.78 (0.6--1)                                                                                                NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  0.71[a](#tfn27-copd-12-141){ref-type="table-fn"} (0.5--0.9)                                                  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Treatment once daily unless stated otherwise.

Significant treatment difference;

data reported for all exacerbations;

includes only severe exacerbations requiring hospitalization/emergency room treatment for ≥24 hours;

dose not approved for use (ACL--FORM dose not approved in EU);

the EXACT instrument assesses patients' breathlessness, cough and sputum, chest symptoms, difficulty bringing up sputum, feeling tired or weak, sleep disturbance, and feeling scared or worried about their condition with a 14-item questionnaire.

**Abbreviations:** ACL--FORM, aclidinium--formoterol; BID, bis in die (twice daily); CI, confidence interval; EXACT, EXAcerbations of COPD Tool; HCRU, health care-resource utilization; HR, hazard ratio; IND--GLY, indacaterol--glycopyrronium; NR, not reported; OL, open-label; RR, rate ratio; TIO--OLO, tiotropium--olodaterol; UMEC--VI, umeclidinium--vilanterol.

###### 

Health status: margin of efficacy of fixed combinations versus comparators in published studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference and study                                                                                               Duration                                                 Treatment                                                             Treatment difference at end point                                              
  ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------------------
  **IND--GLY**                                                                                                                                                                                                                                                                                                                    

  Bateman et al[@b2-copd-12-141] (SHINE)                                                                            26 weeks                                                 IND--GLY 110/50 μg OD vs Indacaterol 150 μg OD\                       −1.09 (NR)                                                                     0.7 (NR)
                                                                                                                                                                             Glycopyrronium 50 μg OD\                                                                                                                             
                                                                                                                                                                             Tiotropium 18 μg OD OL\                                                                                                                              
                                                                                                                                                                             Placebo                                                                                                                                              

  −1.18 (NR)                                                                                                        3.2 (NR)                                                                                                                                                                                                      

  −2.13[a](#tfn34-copd-12-141){ref-type="table-fn"} (NR)                                                            7.3[a](#tfn34-copd-12-141){ref-type="table-fn"} (NR)                                                                                                                                                          

  −3.01[a](#tfn34-copd-12-141){ref-type="table-fn"} (−5.05 to −0.97)                                                7.1 (NR)                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                  

  Vogelmeier et al[@b39-copd-12-141] (ILLUMINATE)                                                                   26 weeks                                                 IND--GLY 110/50 μg OD vs SFC 50/500 μg BID                            −1.24 (−3.33 to 0.85)                                                          6.4 (1.32)

                                                                                                                                                                                                                                                                                                                                  

  Wedzicha et al[@b40-copd-12-141] (SPARK)                                                                          64 weeks                                                 IND--GLY 110/50 μg OD vs Glycopyrronium 50 μg OD\                     −1.9 to −2.8[b](#tfn35-copd-12-141){ref-type="table-fn"} (NR); all *P*\<0.01   NR (1.28)
                                                                                                                                                                             Tiotropium 18 μg OD OL                                                                                                                               

  −1.7 to −3.1[b](#tfn35-copd-12-141){ref-type="table-fn"} (NR); all *P*\<0.05                                      NR (1.29)                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                  

  Buhl et al[@b25-copd-12-141] (QUANTIFY)                                                                           26 weeks                                                 IND--GLY 110/50 μg OD vs tiotropium 18 μg OD + formoterol 12 μg BID   −0.69 (−2.31 to 0.92)                                                          4.5 (risk ratio 1.11)

                                                                                                                                                                                                                                                                                                                                  

  Zhong et al[@b24-copd-12-141] (LANTERN)                                                                           26 weeks                                                 IND--GLY 110/50 μg OD vs SFC 50/500 μg BID                            −0.69 (−2.38 to 1)                                                             NR

                                                                                                                                                                                                                                                                                                                                  

  Wedzicha et al[@b26-copd-12-141] (FLAME)                                                                          52 weeks                                                 IND--GLY 110/50 μg OD vs SFC 50/500 μg BID                            −1.8[a](#tfn34-copd-12-141){ref-type="table-fn"} (NR)                          1.3[a](#tfn34-copd-12-141){ref-type="table-fn"} (NR)

                                                                                                                                                                                                                                                                                                                                  

  **UMEC--VI**                                                                                                                                                                                                                                                                                                                    

  Donohue et al[@b41-copd-12-141]                                                                                   24 weeks                                                 UMEC--VI 62.5/25 μg OD vs Umeclidinium 62.5 μg OD\                    Change from baseline:                                                          
                                                                                                                                                                             Vilanterol 25 μg\                                                                                                                                    
                                                                                                                                                                             OD Placebo                                                                                                                                           

  −0.82[c](#tfn36-copd-12-141){ref-type="table-fn"} (−2.90 to 1.27)                                                 5 (NR)                                                                                                                                                                                                        

  −0.32[c](#tfn36-copd-12-141){ref-type="table-fn"} (−2.41 to 1.78)                                                 1 (NR)                                                                                                                                                                                                        

  −5.51[a](#tfn34-copd-12-141){ref-type="table-fn"},[c](#tfn36-copd-12-141){ref-type="table-fn"} (−7.88 to −3.13)   15 (2)[a](#tfn34-copd-12-141){ref-type="table-fn"}                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                  

  Decramer et al[@b23-copd-12-141] (study 1)                                                                        24 weeks                                                 UMEC--VI 125/25 μg OD[d](#tfn37-copd-12-141){ref-type="table-fn"}\    Change from baseline:                                                          
                                                                                                                                                                             UMEC--VI 62.5/25 μg OD vs Tiotropium 18 μg OD\                                                                                                       
                                                                                                                                                                             Vilanterol 25 μg OD                                                                                                                                  

  0.75[c](#tfn36-copd-12-141){ref-type="table-fn"} (NR)                                                             3 (0.9)                                                                                                                                                                                                       

  1.42[c](#tfn36-copd-12-141){ref-type="table-fn"} (NR)                                                             3 (0.8)                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                  

  Decramer et al[@b23-copd-12-141] (study 2)                                                                        24 weeks                                                 UMEC--VI 125/25 μg OD[d](#tfn37-copd-12-141){ref-type="table-fn"}\    Change from baseline:                                                          
                                                                                                                                                                             UMEC--VI 62.5/25 μg OD vs Tiotropium 18 μg OD\                                                                                                       
                                                                                                                                                                             Umeclidinium 125 μg OD                                                                                                                               

  −0.17[c](#tfn36-copd-12-141){ref-type="table-fn"} (NR)                                                            1 (1)                                                                                                                                                                                                         

  −1.55[c](#tfn36-copd-12-141){ref-type="table-fn"} (NR)                                                            6 (1.3)                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                  

  Maleki-Yazdi et al[@b32-copd-12-141]                                                                              24 weeks                                                 UMEC--VI 62.5/25 μg vs tiotropium 18 μg                               Change from baseline:                                                          

  −2.1[a](#tfn34-copd-12-141){ref-type="table-fn"} (−3.61 to −0.59)                                                 7[a](#tfn34-copd-12-141){ref-type="table-fn"} (1.4)                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                  

  Donohue et al[@b27-copd-12-141] (study 2114930)                                                                   12 weeks                                                 UMEC--VI 62.5/25 μg OD vs SFC 50/250 μg BID                                                                                                          

  0.47 (−1.36 to 2.29)                                                                                              NR                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                  

  Donohue et al[@b27-copd-12-141] (study 2114951)                                                                   12 weeks                                                 UMEC--VI 62.5/25 μg OD vs SFC 50/250 μg BID                                                                                                          

  −1.55 (−3.63 to 0.53)                                                                                             NR                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                  

  **TIO--OLO**                                                                                                                                                                                                                                                                                                                    

  Buhl et al[@b30-copd-12-141] (studies 1237.5 and 1237.6 combined)                                                 52 weeks                                                 TIO--OLO 2.5/5 μg OD[d](#tfn37-copd-12-141){ref-type="table-fn"}\     At 24 weeks:                                                                   At 24 weeks:[f](#tfn39-copd-12-141){ref-type="table-fn"}
                                                                                                                                                                             TIO--OLO 5/5 μg OD vs Olodaterol 5 μg\                                                                                                               
                                                                                                                                                                             OD Tiotropium 5 μg OD                                                                                                                                

  −1.693[a](#tfn34-copd-12-141){ref-type="table-fn"},[e](#tfn38-copd-12-141){ref-type="table-fn"}                   12.7[a](#tfn34-copd-12-141){ref-type="table-fn"}                                                                                                                                                              

  −1.233[a](#tfn34-copd-12-141){ref-type="table-fn"}                                                                8.8[a](#tfn34-copd-12-141){ref-type="table-fn"}                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                  

  **ACL--FORM**                                                                                                                                                                                                                                                                                                                   

  Singh et al[@b28-copd-12-141] (ACLIFORM-COPD)                                                                     24 weeks                                                 ACL--FORM 400/6 μg BID[d](#tfn37-copd-12-141){ref-type="table-fn"}\   Change from baseline:                                                          
                                                                                                                                                                             ACL--FORM 400/12 μg BID vs Formoterol 12 μg BID\                                                                                                     
                                                                                                                                                                             Aclidinium 400 μg BID\                                                                                                                               
                                                                                                                                                                             Placebo                                                                                                                                              

  −1.59 (−3.52 to 0.35)                                                                                             NR                                                                                                                                                                                                            

  −1.36 (−3.3 to 0.58)                                                                                              NR                                                                                                                                                                                                            

  −0.65 (−3.08 to 1.78)                                                                                             NR                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                  

  D'Urzo et al[@b29-copd-12-141] (AUGMENT)                                                                          24 weeks                                                 ACL--FORM 400/6 μg BID[d](#tfn37-copd-12-141){ref-type="table-fn"}\   Change from baseline:                                                          
                                                                                                                                                                             ACL--FORM 400/12 μg BID vs Formoterol 12 μg BID\                                                                                                     
                                                                                                                                                                             Aclidinium 400 μg BID\                                                                                                                               
                                                                                                                                                                             Placebo                                                                                                                                              

  −1.87                                                                                                             5.8                                                                                                                                                                                                           

  −0.13                                                                                                             3.7                                                                                                                                                                                                           

  −4.36[a](#tfn34-copd-12-141){ref-type="table-fn"}                                                                 19.5 (2.3)[a](#tfn34-copd-12-141){ref-type="table-fn"}                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Treatment once daily unless stated otherwise. SGRQ response = SGRQ total score ≤4 units versus baseline.

Significant treatment difference;

range of LSM differences in scores for weeks 12, 24, 38, 52, and 64 (95% CI not reported);

differences in LSM change from baseline to week 24;

dose not approved for use (ACL--FORM dose not approved in EU);

95% CI not reported;

OR not reported.

**Abbreviations:** ACL--FORM, aclidinium--formoterol; BID, bis in die (twice daily); CI, confidence interval; IND--GLY, indacaterol--glycopyrronium; LSM, least-squares mean; NR, not reported; OL, open-label; OR, odds ratio; SFC, salmeterol--fluticasone combination; SGRQ, St George's Respiratory Questionnaire; TIO--OLO, tiotropium--olodaterol; UMEC--VI, umeclidinium--vilanterol.
